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ABSTRACT
Cancer comprises many specific diseases, and it is currently responsible for millions of
deaths worldwide.1 This broad disease profile is a great challenge for personalized oncology.2
Critical for the success of cancer therapy is the exploration of improved methodologies for the
early detection of localized and disseminated tumor cells in patients, where bio-molecular
imaging has become an indispensable tool.2-3 Being one of many different imaging techniques,
optical fluorescence imaging has been translated over the years from the bench to clinical
research, and it is now on the verge of being able to address some of the pressing challenges in
molecular oncology.3
Optical imaging can provide real-time, high spatially and temporally resolved detection
of small cancer foci or establishment of boundaries between malignant and normal tissue during
surgery, which is the primary treatment modality for most solid tumors.2,4-5 Furthermore, optical
signals can provide information on tumor metabolism and biochemistry that helps provide an
understanding of tumors at the molecular level, so as to gain access to the activity of their
biological processes that may yield the capability to provide personalized “on the spot”
treatment.3 Thus, advancing development of new optical fluorescent probes for imaging
techniques has grown exponentially over the years, as these probes continue to revolutionize the
ability to visualize complex biological processes in living systems.
Fluorophores have been used in a wide variety of applications, ranging from medical
diagnostic applications as chemical sensors and molecular probes, to display devices and dyesensitized solar cells.6-7 Although extensive research work has been done on the development of
molecular imaging probes, their use in the clinical setting is still in its infancy. The number of
profluorophores that can have their fluorescence signature selectively and quickly altered by the
presence of a disease-associated enzyme is extremely small, as is the type of disease-associated
enzyme used for probe activation.8
The goal of this thesis is development of a group of small molecule-based profluorogenic
probes and demonstration of their activity with a cancer-associated enzyme, NAD(P)H:quinone
oxidoreductase-1 (NQO1). This goal was attained by completing several different objectives that
will be discussed together with their outcomes in the following chapters of this dissertation.
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CHAPTER 1
INTRODUCTION
1.1

Research goals and aims
An ever-growing area in bio-molecular imaging involves the design of reaction-based,

small-molecule fluorescent probes that have the capability of real-time interrogation of cellular
events with a high degree of specificity and selectivity in their native biological environment.
Such reaction-based fluorescent “smart-probes”9 are especially useful for cancer-related
cytoreductive surgical interventions to provide real-time information on the tumor cell
microenvironment. To date, only a small number of clinically approved fluorescent reporters are
available.10 However, for the most part, these clinically available reporters do not possess the
ability to have their fluorescent signature selectively revealed in response to a cancer-linked
trigger or biomarker, leading to poor delineation between normal and diseased cells. In this
regard, fluorescent probes whose fluorescent reporter signal is turned on by enzyme action hold
great potential in the identification, enumeration, and study of living cancer cells.4,11-12
Therefore, the goal of the work presented in this dissertation is envisioned through the
development of libraries of disease-specific, turn-on fluorescent probes to provide
detection/identification protocols that could assist in fluorescence-guided surgical resection of
cancerous tissues.
After inception of the tripartite sensor concept in the late 1980s, many groups have
exploited this idea in the design of prodrugs in cancer therapy.13-16 However, their use in imaging
probe strategies is still limited.17 The tripartite probe chemistry work presented here involves the
study of three components, namely trigger, linker, and reporter. As illustrated in Figure 1.1, due
to their molecular design, the tripartite probes will readily enter the cytosol of cancer cells, where
rapid NQO1-initiated reduction of the quinone substrate group converts it to an unstable
intermediate. This is followed by a subsequent self-cleavage of the lactone and linker
rearrangement to yield an intensely light-emissive fluorescent reporter that will be retained inside
the cell to provide identification and differentiation of living human tumor cells based on
intracellular enzyme content.
A large part of reporter release kinetics for tripartite probes depends on the electronic and
structural features of the associated linker systems, as well as the trigger group. Quinoidal trigger
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Figure 1.1
Schematic representation of activation of a quinone–based tripartite activatable
“smart probe” inside a cancer cell.
groups with varying substituents have been studied extensively in the McCarley group, to probe
their electronic and structural characteristics and their activation by human NQO1 enzyme. A
main objective of the work presented here involves the study of different linker systems to
design tripartite probes with rapid reporter release mechanisms. A novel N-methyl-para-amino
benzyl alcohol (NMPABA) based self-immolative linker system was employed to study the
kinetics of reporter release from a model probe. The first chapter describes the kinetics of orthoand para- NMPABA based trigger probes, which involves the monitoring of sodium dithionite
initiated production of 4-nitroaniline reporter groups by UV/visible spectroscopy.
Another important aspect in activatable probe design is the achievement of higher signalto-background ratios (SBRs). Outcomes of the kinetic studies were beneficial in designing a
novel imaging probe for NQO1 that was used to complete the second objective. The activatable
probe presented in the second chapter has two unique fluorescent modulating features to achieve
higher SBRs. The well-separated absorption/emission between the probe and the reporter, and
the unique quenching of the probe fluorescence, allowed achieving high SBRs in cellular
imaging experiments.
The use of probe/reporter conjugates with near-infrared excitation and emission energies
is considered essential for successful in vivo fluorescent imaging experiments. Finally, as for the
third objective, the imaging probes were designed by incorporating faster eliminating linker
systems with near-infrared (NIR) fluorophores for future use in routes of in vivo imaging of
NQO1 enzyme.
2

1.2

Cancer imaging: Lighting up tumor cells
Intense research on cancer over the years has dramatically increased the public perception

and clinical knowledge of the causes and biology of cancer, leading to many improved
preventive and treatment strategies. However, cancer still remains the third leading cause of
death in the world, behind heart and infectious diseases, signaling the pressing need for effective
detection and treatment methods.18 In this regard, bio-medical imaging is playing a vital role in
all aspects of cancer management,19-20 including prediction, screening, staging and metastasis,
prognosis, therapy planning, and recurrence.21-31 The number of cells contained within the entire
human body is estimated to be approximately 1014. Because a tumor initially begins with a single
cell, a detectability of 10-14, an incredibly small number, is needed to trace the origin of a tumor.
However, the growth of human solid tumors typically displays ‘Gompertzian’ kinetics,32 as
Newcells
Technologies
for Human Cancer
Imaging
shown in Figure 1.2, where is plotted the number of malignant
as a function
of time.
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1.3

Bio-molecular imaging modalities in oncology
It is often perceived by many that the fate of cancer patients rests upon improved drug

treatment methods. However, most of the patients with solid tumors have a higher chance of
INSIGHT REVIEW
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Figure 1 | Imaging technologies used in oncology. Many macroscopic imaging
technologies (shown above the timeline) are in routine clinical use, and
there have been huge advances in their capabilities to obtain anatomical
and physiological information since the beginning of the twentieth century.
Shown are some examples of bones (X-rays), soft tissue (ultrasound, MRI and
CT rows), three-dimensional organs (CT and MRI rows) and physiological
imaging (MRI and PET rows). Microscopic and other intravital optical
techniques (shown below the timeline) have developed over the past decade
and now allow studies of genetic, molecular and cellular events in vivo.
Shown are surface-weighted, whole-mouse, two-dimensional techniques
(macroscopic reflectance row); tomographic three-dimensional techniques,
often in combination with other anatomical modalities (tomography
row); and intravital microscopy techniques (microscopy row). The
timeline is approximate and is not to scale. BLI, bioluminescence imaging;
CT, computed tomography; DOT, diffuse optical tomography; FMT,
fluorescence-mediated tomography; FPT, fluorescence protein tomography;
FRI, fluorescence reflectance imaging; HR-FRI, high-resolution FRI;
LN-MRI, lymphotropic nanoparticle-enhanced MRI; MPM, multiphoton
microscopy; MRI, magnetic resonance imaging; MSCT, multislice CT;

Figure 1.3

OCT, optical coherence tomography; OFDI, optical frequency-domain
imaging; PET, positron-emission tomography. (PET image reproduced,
with permission, from ref. 4. Diffusion MRI image courtesy of B. Ross 3and
A. Rehemtulla, Univ. Michigan Medical School, Ann Arbor. X-ray image
(left) reproduced, with permission, from ref. 86. Diaphanoscopy image
reproduced, with permission, from ref. 87. Fibre-optic image reproduced,
with permission, from ref. 88. BLI image courtesy of K. Shah, Massachusetts
General Hospital, Harvard Medical School, Boston, Massachusetts. Lifetime
FRI image courtesy of U. Mahmood and C. Salthouse, Massachusetts
General Hospital. DOT image reproduced, with permission, from
ref. 89. FPT image courtesy of G. Zacharakis and V. Ntziachristos,
Massachusetts General Hospital. FMT–MRI image courtesy of
J. Chen, Massachusetts General Hospital. Bright-field image (left)
reproduced, with permission, from ref. 14. Bright-field image (right)
courtesy of T. Mempel, Massachusetts General Hospital. Epifluorescence
image courtesy of F. Jaffer, Massachusetts General Hospital. OCT, OFDI
image reproduced, with permission, from ref. 22. MPM image reproduced,
with permission, from ref. 51. Microendoscopy image reproduced, with
permission, from ref. 17.)

Advancement of different molecular imaging technologies used in oncology.

modalities used in molecular oncology—X-ray, computed tomography (CT), ultrasound (US),
magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT),
4

positron emission tomography (PET), and optical imaging—can be grouped according to the: 1)
type of information obtained (anatomical, physiological, cellular or molecular); 2) resolution
achieved (macroscopic, mesoscopic or microscopic); and 3) energy used (X-rays, positrons,
photons, or sound waves) (Figure 1.3).3,35 CT, MRI, PET, and SPECT are used in routine clinical
practices and for efficacy studies on drugs in clinical trials.3 However, these imaging techniques
have unique applications, as well as advantages and limitations to each.34 For example, MRI and
CT techniques rely purely on energy-tissue interactions, whereas PET and SPECT techniques
depend on the incorporation of reporter probes or contrast agents.36 PET imaging is the most
widespread imaging technique, and many oncologists make decisions based solely on visual
analysis of PET images.33,36 However, the risk of radioactivity, low spatial resolution, and
importantly the high instrumentation cost, somewhat restrict its potential.33 By contrast, optical
imaging techniques based on fluorescence illumination have gained immense attention in both
medical and biological sciences; although they are widely used in the traditional laboratory
setting experimentally, there is clear potential for their translation into the clinic.3
1.3.1

Fluorescence Imaging: a non-invasive, low-cost alternative
Fluorescence, a phenomena first discovered by G.G Stokes37 in the middle of the 19th

century, refers to observation of light emitted by molecules subsequent to their excitation by
light of a particular energy.38 This inherent feature of many molecules is important in numerous
scientific and technological disciplines, namely physics, chemistry, materials science, biology,
and medicine,39-41 out of which medical and biological sciences have rapidly adapted
fluorescence imaging to a great extent. Observation of autofluorescence from endogenous
porphyrins in tumors was one of the earliest applications of fluorescence imaging in the medical
sciences, dating back to 1924.42 Since then, fluorescence imaging has evolved into sophisticated
microscopic and macroscopic imaging systems that, provide a rapid, non-invasive, and low-cost
alternative for the current predominant imaging modalities (CT, US, MRI, PET and SPECT),
thereby showing huge potential in its translation into the clinic. The two main types of
macroscopic imaging techniques are fluorescence reflectance imaging (FRI) and fluorescencemediated tomography (FMT).43 FRI is used in imaging surface (epithelial) tumors and surgically
exposed organs so as to yield obtain two-dimensional (planar) images, whereas FMT and
reconstruction methods provide three-dimensional images for much deeper targets, via the help

5

Published on 23 May 2011. Downloaded by Louisiana State Univers

impairment due to th
Optical imaging relies on photons ranging in wavelength
a potentially fatal d
from the visible to the near infrared (NIR) (500 to 1500 nm
toxicity of gadolinium
wavelength). Charge Coupled Device (CCD) detectors, which
With this said, MRI s
are used for optical imaging, generally show better sensitivity
yielding methods tha
for photons at shorter wavelengths. Within this range, NIR
3,43
of sophisticated
algorithms.
On
the
other
hand,
fluorescence
microscopy
is
a
rapidly
multiplexed
informat
light, ranging from 650 to 800 nm, provides the best visualization
need
fora contrast mat
of deeperthatstructures,
to several
centimeters,
from components
the
expanding technique
has made itup
possible
to identify
cells and cellular
with
By keeping these
surface, as this range is less readily absorbed by living tissue
high degree of selectivity. The two main fluorescence microscopic techniques—multiphoton
combinations of two
(Fig. 3). Shorter wavelength photons are limited to imaging
microscopythe
and surface
laser-scanning
confocal
microscopy—have
been
transformed
from
in
vitro cell imaging’’, can
‘‘hybrid
or immediately subsurface phenomena because
visualization
in vivo
imaging. absorbance
Multiphoton imaging
can and
offer hours
of imaging
with
information
about a p
oftonear
complete
of lightsystems
by oxydeoxynew molecular
prob
Of course,to depth
of penetration is information,
partly related
high spatialhemoglobin.
and depth resolutions
yield three-dimensional
which cannot
be
preclinical examples,
to the strength of the light source, therefore, the signal from
achieved by confocal microscopy set-ups.3 However, confocal microscopic imaging is still
fluorophores with very strong emission can penetrate tissue
widely popular
different
disciplines
in the biological
and medicalemitting
fields, due to itsB.1.1
user- Nuclear/opt
moreacross
deeply.
Numerous
visible-to-NIR
wavelength
friendly andagents
low-cost
It is also
to mention
awarding
of theand optical im
nuclear
are operating
used for procedures.
optical imaging
andnoteworthy
such fluorophores
can
molecular
detected for
with
pico-molar
sensitivity
without
ionizing and Stefan
Nobel Prizebe
in chemistry
the year
2014 to Eric
Betzig, William
E. Moerner,
W. imaging an
radiation. Optical imaging alone (without exogenous probes)
Within this strategy,
Hell for their involvement in the development of super-resolution fluorescence microscopy,44
has been used in clinical practice for detecting blood flow or
to provide quantitati
microscopicblood
route tooxygen
the studyconcentration
of living cells with
highest
level
of
molecular
detail.
in relatively superficial organs
component provides
including the breasts, brain, and eyes. Only two optical imaging
be utilized to determ
1.3.2 In vivo
near-infrared
fluorescence
imaging
reagents; fluorescein and indocyanine green (ICG), have been
and provide physiolog
for (NIR)
use inregion
clinical
practice.
Small
numbers
of targetspectrum
andoffers
probe concentrat
Theapproved
near-infrared
(650–900
nm)
of the
electromagnetic
specific fluorescent probes have been introduced for use during
or organ).43–45 The o
certain advantages for photons to propagate through live tissue much more efficiently than those
surgery- or endoscopy, but none is in common clinical use.
the ability to qualitati
3,45
in the visible region (Figure 1.4).
assist with interventio
or for specific detectio
‘‘always on’’ or tum
probes (discussed late
probes useful for dru
enzyme-specific imagi
tumor targeting.38,39,4

B.1.1.1 Nuclear/opt
positron emitting is
provides even better q
agents.49 PET has hig
quantitative.50,51 With
PET/optical agents h
optical quantum dot
Figure 1.4 Fig.A3 scheme
of the in vivo NIR window and the extinction coefficient attached
value of to a chelatin
A schema of the in vivo NIR window and the extinction
water, and oxy- and deoxy-haemoglobin in the visible to near infrared energy range.46 and to a vascular end
coefficient value of water, oxy- and deoxy-hemoglobin are plotted
ranging from visible to near infrared wavelength.
analog for site-speci
This journal is

c

The Royal Society of Chemistry 2011
6

Ch

indolyl, 2-quinoline and 4-quinoline subclasses. Of these,
the indocyanines are the most widely used as they do
not have the aggregation problems associated with the
other subclasses [6]. Peak excitation of this class is at
760–800 nm, and peak emission at 790–830 nm.

Box 1 Optimization of parameters for in vivo NIR
fluorescence imaging.
Fluorophore properties
Tissue and/or cell targeting
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autofluorescence, which limits the signal-to-background ratio (SBR). The dependence of tissue

Conventional organic fluorophores suffer from significant
common of which are polymethines. One important class
auto fluorescence on excitation light of different wavelengths
is depicted in Figure 1.5. As seen
limitations. First, and foremost, it is difficult to control
of these molecules is the heptamethine cyanines
excitation
andautofluorescence
emission wavelengths.
These
wavelengths
(Figure
2a),1.5,
comprising
benzothiazole,
in Figure
(b), blue benzoxazole,
light excitation
gives the highest
tissue
from
skin,
small

intestine,
Figure
1

and bladder. But under green light excitation (Figure 1.5 (c)), the the autofluorescence
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Figure 1.5

Wavelength–dependent autofluorescence from vital organs and body fluids. (a)

Wavelength-dependent
of vital
organs and
bodily fluids.
(a) Immediately
after sacrifice,
viscera of a hairless,
athymic
white light colorautofluorescence
image of the
animal,
arrows
mark
the location
of thethegallbladder
(GB),
small
nu/nu mouse were exposed. Tissue autofluorescence was then imaged using three different excitation/emission filter sets: (b) blue/green
intestine
(SI) and
bladder
blue/green
nm/505–560
(c) green/red
(525–
(460–500
nm/505–560
nm); (c)
green/red (Bl);
(525–555(b)
nm/590–650
nm); and(460–500
(d) NIR (725–775
nm/790–830 nm).nm);
The fluence
rate provided by
each filter
47
2
555
nm);
(d) NIR
(725–775
nm/790–830
nm).width
set
wasnm/590–650
adjusted to 2 mW/cm
. Toand
compensate
for differences
in emission
filter wavelength
and camera sensitivity, exposure times were
adjusted accordingly. Fluorescence images have identical normalization. For orientation, the white light color image of the animal is shown in (a).
Arrows mark the location of the gallbladder (GB), small intestine (SI) and bladder (Bl).
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of the bladder and the gallbladder is reduced significantly. Finally, with an NIR excitation filter
set (Figure 1.5, (d)), autofluorescence is reduced to a minimum. This feature is important to
achieve better SBR for most in vivo experiments.
1.4 Optical molecular imaging
The interaction of light with tissue components is the basis of optical bio-imaging
methods, which have spatial resolutions that span those of sub-cellular microscopy to organ level
techniques (Figure 1.6).3,50 This photon-component interaction can be based on either
endogenous or exogenous components that give rise to the observed optical molecular contrast.
In endogenous contrast methods, inherent morphological differences, such as nuclear size,
density, and distribution, are utilized to obtain information about the normal and neoplastic tissue
states. A major challenge with endogenous methods is the nonspecific background contrast; thus
numerical and analytical models have to be incorporated to achieve successful diagnosis in the
clinical setting.51 However, one significant benefit with this method is the acquired image does
not rely on exogenous agents, which require regulatory approval for clinical use.50
1980

PIERCE ET AL.

FIGURE 1 – Five classes of molecular-specific optical contrast agent. From left to right in order of increasing size: Small molecules including
glucose and peptides can be functionalized with fluorescent dyes. Aptamers can be designed to form activatable ‘‘smart probes,’’ with fluoresFigure 1.6
classes
ofprobes
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to rightmolecules
in
cence quenched
until targetFive
binding.
Antibody
are generally functionalized
withcontrast
fluorescentagents,
dyes in thefrom
Fc domain.
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smallgold
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functionalized with fluorescent dyes. Aptamers can be designed to form activatable ‘‘smart

direct conjugation to the probe ligand, or indirect binding via a
Nonspecific exogenous contrast agents
probes,’’ with fluorescence being quenched until target binding. Antibody probes are generally
Increasing optical contrast with exogenous agents has tradition- linker segment. Preparation of the optical reporter may also
include surface
functionalization
improve
stability, delivery,
functionalized
dyesintroduce
in the disFc domain.
Targeting
moleculesto can
be coupled
to
ally relied
on nonspecific with
small fluorescent
molecules to either
50
retention
and
specificity.
We
next
discuss
some
of the current
tinct absorbing
or fluorescent optical
properties,reporters,
or to induce
detectablegold nanoparticles and quantum dots.
nanoparticle-based
including
changes in native tissue properties. In most instances, these non- approaches to contrast agent development, each broadly based
specific agents enhance visualization of alterations in cellular mor- upon probe molecules conjugated to optical reporters, covering
phology occurring during transformation from normal to precan- examples spanning a range of physical sizes and molecular
cerous states. A range of vital dyes with absorbing or fluorescent weights as illustrated in Figure 1.
properties including fluorescein, indocyanine green, cresyl violet
acetate, toluidine blue and Lugol’s iodine are currently used in 8
clinical screening. These nonspecific dyes can exhibit some degree Organic fluorophore reporters
Antibodies, antibody fragments and biologically derived peptiof intra- or extracellular localization based on size or charge distribution. Acriflavine is one such agent that binds to nuclear material des can all act as effective probe species, using the amine, carand has been used in clinical trials evaluating confocal optical boxyl or thiol functional groups present within the protein struc-

Exogenous contrast agents can be of two types, namely nonspecific and molecular
specific. In general exogenous agents in general rely on absorption or fluorescence properties of
dyes to provide contrast enhancement between healthy and diseased tissues.50 Molecular-specific
agents are designed with a known disease biomarker targeting moiety conjugated directly or via
a linker to an optically active reporter. These biomarkers include cell-specific proteins and
receptors, and enzymes that get activated, expressed, or upregulated in carcinogenesis-related
processes.
1.4.1

Nanomaterial-based imaging
Many different nanomaterial-based probes have been used in cancer research with great

success.52-54 An overview of the different types of nanoparticles and the images obtained with
these nanoparticle-based probes are depicted in Figure 1.7. These nanoparticle-based probes can
be broadly classified in to two groups: organic species and inorganic nanocrystals (semiconducting quantum dots (QDs) and silica nanoparticles).55 Compared to other contrast agents,
QDs have unique optical and electronic properties, high absorbance cross section, wavelength49,56
www.advmat.de
tunable emission, intense brightness of the signal, and high resistance to photodegradation.
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is limited to superficial sites due to the limited penetration the heavy metals commonly used to synthesize these semicondepth of light, even in the near infrared range where tissue ductor NPs, most commonly cadmium, are highly toxic so their
absorbance is minimal.[26] However, these NPs can also provide 9 use in humans may be limited. Strategies have been developed
contrast in X-ray computed tomography (CT) imaging due to to synthesize cadmium-free quantum dots to improve their
their high densities as compared to human soft tissue, which clinical translation.[31] In addition, use of these QDs for detecenables non-invasive, real-time imaging of the vast majority of tion or diagnosis of cancer is limited to superficial sites such
[27]

In conjunction with diagnostic and therapeutic agents, QDs have been used successfully
in cancer diagnosis and therapy applications with high specificity.65-67 The use of toxic heavy
metals, e.g., Cd and Se., in the synthesis of QDs limits their potential use in human clinical
trials.56 However, strategies have been developed either to avoid using toxic metals68-69 or to
render them biocompatible by covering them with a shell having functionalized (PEG) surface.56
The surface coatings in QDs help improve blood circulation lifetime as a result of minimized
protein adsorption, allowing intracellular distribution and cellular uptake.56 Gao et al. were one
the first to showcase the biocompatibility of QDs in a murine xenograft model, where they used
a surface functionalized QD (CdSe-ZnS) to target a prostate-specific membrane antigen.65 Also,
Gao et al. recently demonstrated high tumor uptake with excellent contrast using NIR noncadmium QDs coated with mercaptopropionic acid.69 Although these studies showed improved
outcomes, use of QDs as an exogenous agents so as to make such a predominant technique is
remain to be seen.
1.4.2

Antibody-based imaging
The high affinity of antibodies toward tumor-specific antigens is the basis for selective

delivery of diagnostic or imaging probes to cancer sites. The pharmacokinetics profile, biodistribution, side effects, and toxicity of some of FDA-approved antibodies are well known,
enabling the translation of antibody-based imaging techniques into clinics with much ease in
comparison to others.
The long plasma half-life of antibodies that result from their increased size and protein
content (~150 kD) is advantageous, thereby providing higher cancer-specific cell uptake in
comparison to imaging modes based on nanoparticle and peptide probes, whose relatively fast
clearance from the body impedes their ability to access and be available at the diseased site.70 In
addition, a wide variety of imaging probes can be chemically linked to antibodies to yield
targeted imaging probes for oncology (Figure 1.8). Especially antibody-conjugated fluorophores
are of great importance in clinical settings, for example indocyanine green (ICG) labeled
antibodies71-74 have long been used in clinical trials with very limited toxicity in humans.70
Furthermore, antibody conjugates, such as fluorescein isothiocyanate (FITC)75 and
IRDye800CW76-77 can be visualized in the visible and NIR regions.70
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Fig. 2 Modality-specific probes
available for antibody labeling for
the purpose of cancer imaging
and localization

resolution of surgical anatomy. The introduction of optical im-

accumulation within the tumor is limited to the enhanced per-

resection in Europe. 5-ALA leverages the differential metabolic
activity of brain tumors and is visible in the red region of the
visible spectrum [29]. While the application of 5-ALA has been
shown effective, limitations such as natural autofluorescence of
brain tissue in the deep red region have made adequate contrast a
challenge. Furthermore, because 5-ALA metabolism is a hallmark of a limited set of cancer types, it is difficult to extend 5ALA beyond malignant gliomas. ICG has shown promise predominantly in sentinel lymph node mapping and is currently
being studied in liver cancer
[30] and breast cancer [31, 32]. The
76-77
greatest barrier for broader application of ICG is the lack of
specificity for cancer, since the primary method of preferential

are over-expressed by tumors such as vascular endothelial
growth factor (VEGF). Rapid growth of tumor tissue beyond
1–2 cm in diameter requires signaling for angiogenesis by
way of increased VEGF production. In preclinical studies,
bevacuzimab-IRDye800 administered in a murine subcutaneous breast cancer model demonstrated modest fluorescence
within flank tumors [33, 34].
78-80
Another strategy is to employ antibodies to molecular
targets that are resident within the tumor such as epidermal
growth factor receptor (EGFR), human epidermal growth
factor receptor-2 (HER-2), and vascular endothelial growth
factor receptor (VEGFR). Conjugating a fluorescent dye to a

meability and retention (EPR) effect.
into the operating room, however, is in its early developFigure 1.8 aging
probes
available
antibody
labeling for the purpose of cancer
Antibody-based
optical imagingfor
during surgery
confers the
ment. To Modality-specific
date, 5-aminolevulinic acid (5-ALA) for use in malig70has been shown to have advantage of targeting tumor-specific markers for fluoresnant glioma surgery is the only agent that
imaging andclinicallocalization.
cence. One such approach utilizes antibodies to ligands that
benefit and is approved for fluorescence-guided cancer

In addition, fluorescent antibody conjugates have been designed for more specific tumor
targets, such as epidermal growth factor receptor (EGFR),

human epidermal growth factor

and vascular endothelial growth factor receptor (VEGFR),76-77 for real-

receptor-2 (HER-2),

time visualization of tumor cell microenvironment.70,81 However, with all of these advancements
Table 1 Radionuclides available
for antibody-based nuclear
imaging

PET

SPECT

in antibody-based imaging techniques, their clinical applicability has been limited due to their
Radionuclide

Half-life

Residualizing

Radionuclide

Half-life

Residualizing

89

78.4 h
100.3 h
12.7 h
14.7 h

+
−
+
+

111

67.3 h
192.5 h
13.2 h
6.0 h

+
−
−
−

Zr
124
I
64
Cu
86
Y

In
131
I
123
I
99m
Tc

long retention in non-targeted tissues, slow clearance from circulation, and tedious optimization
refinement of conjugation chemistry for each antibody–species.81
1.4.3

Peptide-based imaging
The Peptide-based probe molecules provide favorable pharmacokinetic properties when

compared to those of antibody-based strategies. In comprison to high-molecular-weight antibody
conjugates, the much lower molecular weight of peptides leads to high conjugate retention and
better affinity to tumor target sites. Many tumors have been shown to overexpress receptors for
somatostatin (SST) or other peptides,82-86 providing strategies for development of peptide-based
probes for visualizing malignancies. Becker et al. demonstrated that fluorescence- based, SST–
dye conjugates can be used as an alternative to the more conventional radiolabeled SST analogs,
ielding high sensitivities and low detection limits.87 Further, Ke et al. showed the specificity of
epidermal growth factor (EGF)-Cy 5.5 fluorescent contrast agent in the detection of EGF
receptor in human breast cancer xenografts.88 In general, peptide-based probes have fewer
functional residues available for involvement at tumor receptor sites which limits their widespread use.50
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1.4.4

Aptamer-based imaging
Aptamer-based contrast probes are a another promising avenue in cancer diagnostic and

imaging applications. Aptamers are single-stranded nucleic acids that are 20–100 bases in
length89 and can be readily modified at arbitrary positions to form well defined 3-dimentional
structures,90 capable of binding to their targets with high affinity and specificity.91 Aptamers
have the ability to bind to almost any molecule of choice, including proteins, phopholipids,
sugars, and other nucleic acids.89-90 Although similar in nature for their ability to recognize and
bind to target molecules, aptamers hold several advantages over antibody-targeting probes. For
aptamers, 1) well-defined structures provide more resistance than antibodies to pH and
temperature changes, 2) chemical synthesis compared to in vitro or in vivo sytnthesis of
antibodies, means more economical and scalable production, and 3) smaller size versus
antibodies can lead to improved tissue penetration and increased systemic clearance. Formulation
of aptamer-based probes can be achieved in two ways, direct linkage with fluorescent molecules
or by conjugation with nanoparticle-based probes.92-93 Jung et al. showed an aptamer-conjugated
polydiacetylene imaging probe (Figure 1.9),94 that switches its fluorescence when specifically

Figure 1.9
Epithelial cancer cell imaging via fluorescent polydiacetylene molecular probes
conjugated to EpCAM aptamer.94
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resulted. Nevertheless, Robert Campbell succeeded over cells shows that the virus can pass directly from one cell to
many cycles of directed evolution in generating a monomeric another through specialized transient adhesions dubbed
red FP (RFP), which made protein fusions much more virological synapses (Figure 13). If the virus can really
reliable.[55] He, Nathan Shaner, and Lei Wang then engineered spread between host cells without even transiently exposing
an extensive palette of monomeric FPs whose emission itself to the extracellular milieu where antibodies could
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Figure 12. Monomeric and tandem dimeric fluorescent proteins derived from Aequorea GFP or Discosoma RFP, expressed in bacteria, and purified.
[56, 57]
This photo
is a time
exposure
of fluorescences
at different
wavelengths
and viewed
throughderived
different cutoff
SHMGFP
= somatic
Figure
1.10
Monomeric
andexcited
tandem
dimeric
fluorescent
proteins
fromfilters.
Aequorea
102
hypermutation.
or Discosoma RFP, expressed in bacteria and purified.
Angew. Chem. Int. Ed. 2009, 48, 5612 – 5626

! 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

www.angewandte.org

The green fluorescent protein (GFP)101-103 was one was one of the first fluorescent

proteins to be used for in vivo imaging.100 A main drawback of GFP is its low emission
wavelength (∼510 nm), rendering it difficult for clinical in vivo applications. However, work
13

5619

jellyfish, was to measure and monitor calcium ions within various bio- and track cells in intact living organisms [55]. For example, a GF
logical systems, mainly single cells [40, 41]. These pioneering studies labelling system was used to validate the hypothesis that human bon
provided the basis for the design and development, only few years marrow–derived mesenchymal stem cells (MSC) possessed tropism
later, of novel methods for incorporating the obelin apoprotein and for brain tumours, and thus, they could be used as vehicles for deliv
mRNA isolated from the hydroid, Obelia, into the cytoplasm of intact ering glioma therapies [56]. Novel molecular chimeras have bee
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Figure 1.11 Schematic representation
of major BLI applications. Bioluminescence-based
assays are currently being applied for (A) detection of biological molecules, (B) gene/protein
expression and intracellular trafficking, and (C) implanted cell distribution and function.112

in bioluminescence allows detection of extremely low concentrations of analytes, over
fluorescent techniques, however, lacks the ability to provide absolute quantification of target
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signal.100 These light-emitting molecules have been used in a wide variety of applications,
including: immunoassays; binding assays; tracking of cells, in particular dividing cells such as
tumor cells,113,116 immune cells117 and bacterial cells;118 intracellular assays for monitoring
biological molecules, like ATP and calcium; and genetic assays involving regulation and
detection, to name a few.112,119
1.5

Small-molecule fluorescent probes: promising approach for biomolecular imaging
A complete understanding of a living system requires methods to probe cells and discrete

bimolecules within their native biological milieu. Small molecule-based fluorescence imaging
offers a powerful approach to interrogate biological processes at the molecular level in real time
with high temporal and spatial resolution.120 The widespread use of confocal, two-photon, and
epifluorescence microscopy and the development of novel fluorescent imaging probes help
monitor intra- and extracellular biological events with high selectivity and sensitivity.121 The
challenge is to design probes that can respond to cellular trigger events in a complex biological
mixture by utilizing differences in chemical reactivity and levels of overexpression of the target
analyte.
1.5.1

Properties of fluorescent probes
The natural product quinine is believed to be the first reported fluorophore,122 dating back

to the late 19th century.123 The invention and later commercialization of the fluorometer in the
1950s led to a huge outburst in fluorescence based bioanalytical techniques, where much of the
attention has been directed toward the development of novel or improved fluorescent molecules
with desirable properties for applications in biological environments.124 To date, a vast collection
of biologically significant small-molecule-based fluorescent probes have been constructed, with
a set of core scaffolds, mainly spanning the visible region of the electromagnetic spectrum
(Figure 1.12).123
The use of fluorescence-based probes for biomaging applications must meet stringent
requirements.121 For these probes to be successful in biological environments, they should
possess resonable kinetics in water under biological constraints of physiological pH, high salt
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Figure 1.12 Plot of fluorophore brightness (ε x Φ) vs the wavelength of maximum absorption
(λabs) for the major classes of fluorophores. The color of the structure indicates its wavelength of
maximum emission (λem). For clarity, only the fluorophore moiety of some molecules is
shown.123
content and large excess of reactive nucleophilic thiols such as glutathione and cysteine.121 Also,
it is critical these probes work independently without interacting with endogenous cellular
processes, and not to produce any toxic byproducts to living systems.121 In addition, the desired
chemical and photophysical properties of the fluorophores includes: hydrolytic stability;
lipophilicity in the context of membrane permebility; water solubility; cellular retention; and
high optical brightness (ε x Φ), which accounts for the efficiency of both light absorption (λabs)
and the emission (λem) of a particular fluorophore.121 Also, it is preferable to have the excitation
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and emission profiles in the visible or near-infrared regions, or be amenable to two-photon
excitation.121
1.5.2

Modulation of fluorescence
An important aspect in biomolecular imaging is attainment of a high quality optical

signal from the target of interest in contrast to the background and other interfering species.
Modulation of fluorescence mainly through photo-induced electron Transfer (PeT),8,125-126
Förster resonance energy transfer (FRET),127 and internal charge transfer (ICT)128-132 processes
help achieve this desired success.133-134 Also, intramolecular cyclization is another rational and
important strategy to modulate fluorescent properties, especially in xanthene fluorophores such
as fluorescein and rhodamines.135 In general, these photophysical and chemical mechanisms
provide fluorescent probes with the ability to show a turn-on or emission increase, or a shift in
excitation/emission profiles, so as to provide the necessary optical contrast from the background.
The large number of small-molecule fluorescent probes constructed by these modulating routes
can be broadly classified into two types: intensity-based and ratiometric probes.120,136 A major
limitation in intensity-based probes is the inability to account for variabilities in excitation and
emission efficiency, probe environment, and probe distribution events that are important for
quantification of the measured fluorescence intensity.130 In contrast, ratiometric imaging is based
on the measurement of fluorescence emission/excitation intensities at two different wavelengths,
which allows internal calibration of reacted and unreacted probe to minimize artifacts that may
arise from environmental factors, therby providing quantitative fluorescence measurements.120
In general, ICT and FRET are the two most commonly exploited fluorescence modulation
techniques used in the design of ratiometric fluorescent probes, while PeT and spirocyclization
mechanisms are used widely in intensity-based probe strategies.
1.5.2.1 Internal charge transfer (ICT)
Fluorophores with electron-donating (often an amino group) group conjugated to an
electron-withdrawing group show very different dipole moments in the ground state and lowest
energy singlet excited states.137 This difference in dipole moments gives rise to the push-pull
nature of these fluorophores undergoing ICT from the donor to the acceptor upon excitation of
light.137-139 Based on the alteration of the asscoiated electronic properties, amine-substituted

17

naphthalimide scaffolds have been widely used in ICT-based fluorophore design strategies, due
to their change in excitaiton/emission profiles. Some recent examples of ICT-based probe
development includes, Cu2+ and Hg2+ sensing in aqueous media,140-141 nitoreductase142 and
hydrogen peroxide130 detection in biological media, mitochondrial hydrogn sulfide imaging,143
and cancer cell imaging.8,126
1.5.2.2 Förster resonance energy transfer (FRET)
FRET is a distance-dependent interaction between the electronically excited states of two
fluorophores, in which excitation energy is transferred from a donor to an acceptor through long
range dipole-dipole interactions (Figure 1.13 (a)).120,138 The use of such FRET energy platforms
a)

b)

Figure 1.13 a) Schematic of the FRET process, and b) Ratiometric fluorescent probes based
on analyte-induced cleavage of FRET dyads.120
require the donor emission spectrum to have a favorable overlap with the acceptor absorption
spectrum, and the highest ocuupied molecular orbital (HOMO) and the lowest unoccupied
molecular orbital (LUMO) energy levels of the acceptor should be located within those of the
donor to avoid quenching of the acceptor fluorescence.144 The typical design strategy of FRET
probes is depicted in Figure 1.13 (b), where in the absence of an analyte, the probe shows the
emission of the acceptor upon excitation at the donor due to FRET. But in the presence of the
analyte, FRET is turned off due to the separation of the donor and the acceptor, giving rise to the
emission of the donor instead of the acceptor. Long et al. synthesized a FRET-based thiol probe
with a bodipy donor and a rhodamine acceptor to detect free thiols in bological fluids.145 Yuan et
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al used the same donor-acceptor dye pair as Long et al, but with a different linker chemistry, and
they were able to achieve unprecedented selectivity toward aminothiols.146 In different work,
Yuan and coworkers showed ratiometric imaging of endogenously produced nitric oxide using a
coumarin-rhodamine donor-acceptor pair.147 However, in this work FRET was achieved through
a spirocyclic ring opening of the rhodamine dye instead of the commonly employed bond
breakage for the separation of the donor-acceptor pair.
1.5.2.3 Photo-induced electron transfer (PeT)
Intensity-based probes commonly use PeT quenching to control their fluorescent
properties with regard to analyte detection. In general, a charge transfer complex is formed
between an electron donor and an electron acceptor, which then returnsNovel
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theimaging
ground
state of cellular functions
techniques
without emission of a photon; this is basis for the PeT quenching of the probe. Unlike in
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Later, Ueono et al. used the same fluorescein scaffold to demonstrate PeT through
electron transfer in the opposite direction, namely from the excited xanthene fluorophore to the
benzene moiety (donor-excited PeT; d-PeT) to develop probes for the detection of reactive
oxygen species (ROS).134
1.6 Applications of small-molecule fluorescent probes
A plethora of biological imaging applications have used small-molecule fluorescent
probes as biomolecule labels, enzyme substrates, environmental indicators, and cellular stains, to
study the dynamic intracellular processes in living cells (Figure 1.15).
A

B

C

D

Figure 1.15 Biological applications of small-molecule fluorophores. A) Site-specific labeling
of a biomolecule by an orthogonal reaction between two functional groups (red). B) Enzyme
substrates: (i) enzyme-catalyzed removal of a blocking group (red) elicits a change in
fluorescence; and (ii) enzyme catalyzes the cleavage of a labeled biomolecule (red) with
concomitant decrease in FRET. C) Environmental indicators: (i) binding of an analyte (red)
elicits a change in fluorescence; (ii) protonation of a fluorophore elicits a change in fluorescence.
D) Staining of subcellular domains by distinct fluorophores.123
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1.6.1

Small-molecule-based fluorescent probes used in identification of disease biomarkers
Reactive–oxygen and nitrogen species (ROS and RNS, respectively) are essential

elements that serve as signalling species that deliver messages to cellular compartments in
response to physiological variations; they assist in maintaining normal organ activities.149
Alteration in ROS and RNS levels are associated with many human health conditions, including
neurological diseases, artherosclerosis, cancer, and diabetic complications.150 Thus, it is
important to identify variations of these reliable biomarkers for early identification of disease
development that may follow.150
Much work has been done to identify cellular variations in ROS due to singlet oxygen
(1O2), hydrogen peroxide (H2O2), and hypochlorus acid (HOCl) as well as RNS associated with
nitric oxide (NO), and peroxynitrite (ONOO-) through small-molecule fluorescent probes with
high sensitivity and selectivity.121 Chang and coworkers pioneered the hydrogen peroxidemediated conversion of arylboronates to phenols for H2O2 detection. Peroxyfluor-1 (PF1), is the
first fluorescence probe for selective imaging of H2O2 in biological systems, based on a
xanthenone scaffold they developed.151 Chang and others further explored the boron deprotection
trigger strategy to develop ratiometric,130 targetable,152-153 trappable,154-155 and in vivo probes156
that covered the fluorophore emission range from the visible to the near-infrared region.151,157-161
In addition to the boronate trigger strategy, Nagano and co workers used dicarbonyl cleavage
reactions to develop the d-PeT modulated fluorescein probe, NBzF, to visualize endogenous
H2O2 production in macrophages and cancer cells.162 Libby’s group163 and Nagano’s group164
reported fluorescein- and rhodamine-based fluorescent probes for detection of HClO, while Yang
and coworkers used a simple and water-soluble p-methoxyphenol derivative to achieve
colorimetric and fluorometric detection of HOCl in aqueous systems.165
Nagano and coworkers were the first to use fluorescence based, diaminofluorescein
(DAF), to assay NO production in living cells.166 This was followed by the development NO
imaging probes with diaminorhodamines (DARs)167 and diamino probes on Bodipy168 and
cyanine169 scaffolds. Yang et al. developed HKgreen-1 probe that releases the highly fluorescent
dichlorofluorescein (DCF) reporter in the presence of peroxynitrite.170 In addition, Sun171 and
Peng172 used BODIPY- and rhodol-based probes, to image peroxynitrite in living cells.
Perturbation of cellular thiol homeostasis can reveal insights into several disease
conditions. Thus, monitoring cellular bio-thiol levels—mainly glutathione (GSH), cysteine
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(Cys), homocysteine (Hcy), and hydrogen sulfide (H2S)—provides valuable information on
cellular oxidative stress levels associated with these diseases. A commonly deployed strategy in
H2S imaging involves the H2S-mediated reductive cleavage of azides to amines.121 Based on this
azide reduction strategy, the Chang lab developed two Sulfidefluor SF1 and SF2 probes,173 Yu et
al. reported a ICT-based cyanine,174 and Montoya et al. reported a napthalimide dye175 as H2S
probes. Both Maeda et al.176 and Wang’s laboratory177 employed the thiol reactivity toward the
2,4-dinitrobenzenesulfonyl functionality to develop probes for monitoring a wide range of
biologically relevant thiols.
Metal ions play important role in all life forms and are responsible for osmotic regulation,
catalysis, metabolism, and signaling.127 Metals that play a critical role in biology include, the
highly abundant sodium, potassium, calcium, and magnesium, as well as transition metals
including iron, zinc, copper, manganese, cobalt, and nickel that are found in trace amounts.127
Cells tightly regulate these metal pools, as mismanagement can result in several disease
conditions.178-179 Fluorescent probes help track labile biological metal ion pools to help assess the
contribution and significance of these metals to healthy and disease states. Chang and coworkers
developed a BODIPY-based fluorophore CS1,180 and Taki and coworkers made FluTPA2,181
based on xanthenone scaffold for sensitive detection of ionic copper pools in living cells. Petrat
et al. used a fluorescein-based Phen Green SK to study labile iron pool in cultured
hepatocytes.182 Hariyama et al. developed the first Fe2+-selective probe, RhoNox-1, which is
based on a rhodamine scaffold.183 Many Zn2+ probes have been developed using various
fluorescent scaffolds, including BODIPY derivatives,184 rhodamine,185-186 coumarin,187 and
tricarbocyanine.188
1.7 Small-molecule probes for cancer imaging
Application of small-molecule-based fluorescence imaging has branched into many areas
in the biological field, out of which, their involvement in cancer imaging has grown to great
heights. From early detection and diagnosis tumor sites to surgical removal of diseased tissues,
small-molecule based fluorescent probes provide great benefits in cancer therapy and
management. Currently at its developmental stage, fluorescent probes help shine new light on
tumors thereby improving surgical molecular navigation, to cause a paradigm shift in cancer
surgery.5 Even with advancement of endoscopic, laproscopic and robotic technologies, surgery
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in the present day is still largely based on anatomy, traditionally seen by white-light
illumination.4-5,9 Thus, visual navigation through the surgical field is challenging, as most of the
tissues in the body appear as various shades of white to pink (nerves, cartilage, muscle,
connective tissue) or red to deep-red (blood vessels), thereby limiting the accurate identification
of surgical margins between healthy and diseased tissues.5
In this regard, fluorescent probes aids in visual enhancement of the surgical field, which
helps provide better surgical outcomes in comparison to traditional white-light reflectance,
yielding improved patient outcomes, and decreased operating time and cost.5 Currently, the only
FDA approved fluorescent probes used to assist intra-oprative resection are indocyanine green
(ICG)2,189-190 and fluorescein sodium.191 ICG has been used clinically for over 50 years in
evaluation of liver blood flow, cardiac output, and opthalmic angiography.2 It has a favorable
uptake in tumor sites, but has a strong biniding tendency to albumin. This albumin binding alters
the ICG spectra and decreases the quantum yield efficiency from approximately 15% in
deionized water to 5% in blood.5,192
1.7.1

Probe design strategies: targeted vs activated
The need is great to develop a diverse set of fluorescent probes for in vivo use in cancer

therapy, in particular fluorescence-guided surgery (FGS).5 Apart from toxicity issues, a major
impediment in fluorescent probe development is achievement of high signal-to-background ratio
(SBR) values,32,193 which in the case of FGS is the tumor-to-background ratio (TBR).32,193
Although cure is the main concern in cancer surgery, preservation of important body
components, such as blood vessels, and nerves, is considered equally important in achieving
optimal patient outcome. Thus, the challenge in FGS is to identify positive margins; defined as
tumor cells being present at the cut edge of the surgical specimen, with high precision and
accuracy for better prognosis and to help prevent recurrence.5
The development of fluorescent probes possessing mechanisms capable of overcoming
the background caused by nonspecific signal or nearby normal cells/tissues could help achieve
this success. This is possible by either 1) maximizing signal from the target, 2) minimizing signal
from the background, or 3) doing both.46,194 Inclusion of the above factors in the design process
has the potential to lead to the development of superior fluorescent probes with high sensitivity,
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conjugated to a tumor-specific targeting moiety that directs the probe into tumor sites away from
the normal healthy tissues. These types of probes are commonly internalized by cancer cells via
receptor-mediated endocytosis that helps retain the always on probe inside the cell, thereby
preventing “bleeding” of fluorescence from diseased cells to normal tissues.195 Because probe
fluorescence is always on, adequate time has to be allowed for probe clearance from the body
before imaging, which is necessary to obtain useful TBRs. Furthermore, the always-on probes
have minimal capability of imaging tumors in kidney, bladder and liver that are along the
excretory pathway, due to high background fluorescence.195 In contrast, activatable probes
exhibit minimal fluorescence when they are bound to a quencher, but generate light only upon
release of the quencher in the malignant tissue, thereby resulting in higher tumor-to-background
ratios than conventional ‘always-on’ probes. Moreover, unlike ‘always on’ probes there is no
need to wait for clearance of the probe from the body, but only the need to wait for their
activation.194
1.7.2

Enzyme activatable small-molecule-based fluorescent probes
Enzymes are crucial in catalyzing a variety of biochemical processes that help regulate

health, and often times disease leads to their deregulation and vice versa. Therefore, the ability to
track changes in enzyme expression levels provides a good path for disease monitoring. As
described earlier, enzyme-activatable probes, have opened up a new window for the researcher
and clinician to follow enzymatic activity in real-time and with greater sensitivity. A common
strategy in the design of activatable profluorophores involves the incorporation of a peptide
sequence between the quencher and the fluorohore that can be specifically cleaved by a tumorenriched protease, such as cathepsins, caspases, and matrix metalloproteinases.196-201 Other
commonly

studied
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2.214
As discussed earlier, optical-based cancer imaging will benefit from having high TBRs,
a possibility with activatable probes, but enzyme activation steps can suffer from being slow
often being on the hours to days time frame, which decreases their applicability in routine or
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real-time clinical use.135 Urano and coworkers developed a rhodamine-based probe, gGluHMRG, and demostrated real-time imaging of γ-glutamyltranspeptidase (GGT) enzymatic
activity associated with human cancer cells. In the presence of membrane bound GGT, the gGluHMRG probe displayed fast activation (within minutes).203 Also, they showed for the first time
the use of enzyme-activatable probes in topical use by their being spray on GGT-expressing
tissue surfaces.203 Recently the Hasserodt laboratory reported a novel strategy in activatable
probe design, where probe activation was achieved through two consecutive enzyme activation
steps by β-galactosidase and leucine aminopeptidase.215 This type of “dual gating” probe design
provides highly selective disease recognition when overexpression of one enzyme could be
characteristic of more than just one disease condition.215 Another less exploited route in the
design of smart probes involves the incorporation of a trigger/quencher group that is activated
only in the presence of an overexpressed tumor-associated reductive enzyme (i.e., NAD(P)H:
quinone oxidoreductase-1).126,216
1.8 NAD(P)H: quinone oxidoreductase-1 (NQO1)
In the late 1950s, Earnster and Navazio first isolated from rat liver homogenates and
characterized the first member of the NQO family, which was later named NQO1 (EC 1.6.99.2);
DT-diaphorase. The isolation of vitamin K reductase by Martius and coworkers demonstrated its
structural similarity to NQO1. The NQO gene family has four genetic loci known as NQO1,
NQO2, NQO3, and NQO4; vertebrates carry the genes for NQO1 and NQO2, a homologous
NQO3 subfamily is found in eubacteria, and NQO4 subfamily is present in fungi.218 The Amzel
lab first reported the crystal structure of rat liver NQO1 (Figure 1.17),217 and his group later
reported the structure of the complex of human NQO1 with duraquinone (DQ), a NQO1
substrate.219
From these structures it was termined that NQO1 is a homodimer of two interlocked
monomers with a molecular weight of a 60 kDa. Each monomer contains a non-covalently bound
molecule of flavin adenine dinucleotide (FAD) and has two separate domains: a catalytic domain
and a smaller C-terminal domain. The catalytic site has three distinct regions; 1) an FAD binding
site, 2) an empty NAD adenosine site, occupied by the hydrophilic adenine-ribose portion of
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that are good substrates of DT-diaphorase will be more cytotoxic under normoxic
s but with lower hypoxia selectivity while prodrugs that are 27
good substrates of a oneeductase but poor substrates of DT-diaphorase usually possess good hypoxia selectivity.
o been shown that hypoxia selectivity of quinone-containing prodrugs is very sensitive to
modification; slight changes on quinone core structure could result in substantial reduction
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The catalytic activity of NQO1 follows a ‘ping-pong bi-bi’ mechanism, due to the
occupancy of the catalytic active site by both cofactor and substrate. In this mechanism,
NAD(P)H first occupies the active site and transfers its hydride to the N5 of the FAD, and then
the resulting oxidized cofactor leaves the site to be replaced by quinone substrate. Hydride
transfer from FADH results in the reduction of the quinone to a hydroquinone, which then
departs so as to resume the catalytic cycle (Figure 1.18 (b)).
Further, as depicted in Scheme 1.1, the overall reduction process involves the His 161
and Tyr 155 residues in the active site. Also, in the final stage of the quinone reduction process,
hydride transfer first forms ionized hydroquinone intermediate (hydroquinolate), which then
obtains a proton from bulk water to form the fully reduced hydroquinone species, thereby
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completing the catalytic cycle.223
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Scheme 2 Mechanism of the two-electron reduction of quinones by NQO1.

healthy tissue, as illustrated for non-small cell lung cancer cells in
substrates
for NQO1
Scheme 1.1 Mechanism of the two-electronQuinone
reduction
of quinones
by NQO1.221
Fig. 6B,36 may be a result of several factors. Firstly it may give the
Although NQO1 can catalyze the two-electron reduction of a
tumour cell some sort of advantage to have NQO1 switched on
broad range of substrates, as its name implies, its major group of
and expressed. Secondly, NQO1 may be part of a stress response
substrates are quinones. Its role in the metabolism of endogenous
signalling system and tumour cells may be continually activated
quinones such as the ubiquinones 1 and a-tocopherolquinone 16
and in a state of “stress”. A further explanation is that NQO1 is
has already been discussed, as has the bioactivation of MMC 13.
only elevated in solid tumours (not leukaemias), and solid tumours
28
However, the flexible nature of the active site can accommodate a
are most often derived from epithelial cells. Epithelial cells are one
wide range of quinone substrates including the natural products
of the cell types that normally contain NQO1 and hence it may
geldanamycin 14 and streptonigrin 15 (Fig. 3), the benzoquinones
just reflect the cell of origin for the solid tumour.
AZQ, MeDZQ and RH1 17, the naphthoquinone b-lapachone and
NQO1 gene expression is regulated by two elements, the

1.8.2

Role of NQO1 in the cellular environment
In cells, as determined in studies using rat liver, NQO1 is considered to be mainly

confined to the cytosol (84% of the total NQO1 amount), and some presence is indicated in
mitochondria (13%), microsomes (2%), and the Golgi apparatus (1%).224-225 Winski et al.226
reported the presence of NQO1 in the nucleus determined by immunocytochemical staining;
however, the mechanism of nuclear localization still remains unclear.227 Also, NQO1 has been
found to be associated with the mitotic spindle.228 NQO1 is involved in a number of different
functions (Figure 1.19), which revolve around its ability to reduce a broad spectrum of quinone
compounds, including simple quinones, quinone-imines, nitro, and azo compounds.229 The
protective role of NQO1 was deduced through dicoumarol and menadione treatment assays,
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I). However,
hydroquinones
are also potentially reactive metabolites and if not conjugated and/or excreted may
undergo bioactivation via autoxidation or,29in the case of some antitumor quinones, by
rearrangement reactions (Fig. I). Thus, even from a simple chemical perspective the
overall contribution of NQOI to toxification/detoxification will depend on the
reactivity and properties of the hydroquinone that is generated (Cadenas et al., 1992;
where dicoumarol is responsible for the inhibition of NQO1 and the menadione leads to the

one-electron reduction (e.g., by NADPH-cytochrome P450) of electrophilic quinones, can
autooxidize causing oxidative stress; whereas, the two-electron reduction (by NQO1) product
hydroquinone could be further conjugated and excreted through the kidney, providing
chemoprotection.220,229 However, if not conjugated, hydroquinones can also undergo
bioactivation via autoxoidation or, in the case of some antitumor quinones, by rearrangement
reactions (Figure 1.19). Thus, the overall contribution of NQO1 toxification/detoxification relies
on the fate of the hydroquinone that is generated. Other cellular functions of NQO1 includes: 1)
acting as coenzyme Q (ubiquinone) reductases, to protect membrane components of the cell from
free radical damage, 2) stabilization of p53, a major tumor suppressor gene, 3) induced in
oxidative stress environment, and scavenge superoxides, among others.230-232
1.8.3

NQO1 in cancer therapy
NQO1 is overexpressed in a variety of solid tumors (e.g., non-small cell lung, pancreas,

breast, ovarian, colon)221,233-234 at levels 2–50 fold greater than in normal tissues, making it a
prime target for the activation of cancer chemotherapeutic agents.227 A major approach in cancer
therapy is the design of inert prodrugs, which are converted to an active drug by enzyme action.
Such methods involve the use of quinone-containing prodrugs with cytotoxic agents that get
selectively activated either by the hypoxic environment of tumor cells or by the two-electron
reducing enzyme NQO1.222 Some of the quinone-containing drugs include Mitomycin C (one of
the earliest clinically used alkylating agents), indolquinone-based E09, and benzoquinone-based
AZQ.233 Although, weaker compared to quinone reduction, under aerobic conditions NQO1 is
capable of reducing nitro compounds through 2-, 4-, or 6-electron reductions, to produce nitroso,
hydroxylamine and fully reduced amine species.220 One specific example for utilization of the
nitroreductase activity in NQO1, leads to the formation of a cytotoxic antitumor compound in
rats, namely a nitrophenylaziridine, CB1954.220 The bio-activation of CB1954 by the human
form of NQO1 is sufficiently slower compared to rat NQO1, decreasing its therapeutic potential
in humans. However, an isoform of NQO1, namely NQO2, showed dramatic increase in
cytotoxicity of CB1954 in human cancer cell lines.220 NQO2 differs from NQO1, with its use of
a smaller dihydronicotinamide riboside (NRH) instead of NAD(P)H as the cofactor and higher
nitro reductase ability.235-236 Although NQO2 overexpression in cancers is much less defined,
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efficient reduction of nitro compounds by NQO2 opened up a new area for antitumor prodrug
design strategies.235
Another use of NQO1 in cancer therapy involves the development of mechanism-based
inhibitors. These types of inhibitors provide a novel strategy for treatment of tumors expressing
NQO1, whereby inhibition of NQO1 leads to the accumulation of intracellular superoxide, which
is known to cause cell death.237 The anticoagulant dicoumarol is used in NQO1 inhibition assays,
but is considered as a nonspecific competitive inhibitor of NQO1.237 Further, Cibacron blue,
chrysin,

7,8-dihydroxyflavone

and

phenidone,

also

competitively

inhibit

NQO1.233

Indolequinone-based inhibitors have been studied been widley to provide specific and potent
inhibitors for NQO1. ES936 is one such inhibitor, where reductive activation by NQO1
generates a reactive iminium ion intermediate, which then alkylates a tyrosine residue at the
active site of NQO1, inhibiting its quinone reductase activity.237
1.8.4

NQO1 detection and imaging through profluorogenic substrate probes
The overexpression of NQO1 in tumors have provided an important biomarker for the

development of reductively activated prodrugs, antitumor compounds, and liposomal drug
delivery systems. An avenue that has not been explored to its full potential involves the
development of profluorogenic substrate probes that can be reductively activated in the presence
of NQO1 enzyme. Such avenues could be useful in imaging cancer cells that overexpress NQO1,
ultimately leading to the development of enzyme-activatable profluorogenic probes for
fluorescence-guided surgical resection of cancerous tissues. Huang et al. reported two different
NQO1 activatable latent fluorophores BQRh238 and BQc,239 based on the rhodamine 110 and
coumarin scaffold respectively. However, their intended application was in the development of
fluorescent-based analyte discrimination through an enzyme-coupled glucose dehydrogenase
assay system. Recently, William Silvers, one of my former colleagues, was able to develop two
different turn-on probes for NQO1 detection.126,240 The first probe was not successful in imaging
applications due to reduction of its reporter form in the cellular environment; however, the
second probe, Q3NI126 (the first reported NQO1 turn-on probe), was successfully used in the
detection and imaging of NQO1-positive cancer cell lines with significant figures of merit. A
main problem associated with Q3NI was its overlapping absorption and emission profile with its
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free dye counterpart (NI) that gave rise to a low signal-to-background ratio. Also, emission of the
free reporter (NI) is in the blue region, a limiting factor for potential in vivo use of Q3NI.
1.9
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CHAPTER 2
SUBSTITUENT EFFECT ON NQO1 TRIGGER GROUP AND KINETICS OF
SELF-IMMOLATION
2.1

Introduction
In recent years, there has been a remarkable interest in the development of activatable

probes that are triggered by endogenous enzymes associated with inflammatory diseases and
cancers.1 Such systems provide better understanding of cellular processes, in the design of
prodrug systems, and specifically to design smart optical bio-probes suitable for bio-molecular
imaging.2 Overexpression of enzymes in certain cancer tissues provides a gateway to develop
such systems, where NAD(P)H: quinone oxidoreductase-1; a subgroup of reductase enzymes,
has become of great interest.3 A significant amount of research has been directed towards
studying the molecular structure and behavior of NQO1 using crystallographic techniques with
substrates, such as duraquinone (PDB accession code 1DXO) or inhibitors, including dicoumarol
(PDB accession code 2F1O)4-8
Research work over the years has shown that the ability of NQO1 to reduce quinone and
quinoidal compounds can be used in the development of activatable prodrug9 and antitumor
compounds.10-11 Although variants of quinone propionic acid trigger groups with mustard9 and
oxindoles12 moieties have been tested in prodrug therapies, little is known about some simple
quinones and their reactivity towards human NAD(P)H:quinone oxidoreductase-1 enzyme. Thus,
it is important to investigate the interaction of different simple quinone trigger groups with
NQO1, and to understand and seek possibilities of utilizing them in the development of
endogenously triggered prodrugs, drug delivery vesicles, and imaging agents.
As generalized in Figure 2.1 the tunability of the quinone trigger groups can be achieved
with the change of substituents in R1, R2, R3, and R4 positions. A family of tunable quinone
propionic acid trigger groups were synthesized by two previous colleagues Dr. Nicole M.
Hollabaugh3 and Dr. Maria F. Mendoza3 in the McCarley group; in the first part of this chapter is
presented my synthesis of one of those trigger groups, herein denoted as QMeO-COOH.
3

This chapter reprinted with permission from Mendoza, M. F.; Hollabaugh, N. M.; Hettiarachchi,
S.U.; McCarley, R.L.; Biochemistry, 2012, 51, 8014-8026. Copyright (2012) American Chemical
Society.
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Reduction and cyclization of quinone propionic acid (QPA) trigger groups.3

Also, the carboxyl functionality of the quinone propionic acid trigger group is important,
as it can be derivatized to an amide by coupling reactions with free amine groups of lipids, drugs,
and dyes to develop reductively activated liposomes, prodrugs, and imaging agents.
Since its introduction by Katzenellenbogen in 1981,13 the tripartite sensor concept has
provided a new paradigm shift in the design of profluorophores and prodrugs. Tripartite, refers to
being a three-part compound that includes a trigger, a linker (or a spacer), and a reporter unit
(Figure 2.2).14 The reporter unit could be any one of the following, namely a lipid (liposomes), a
drug (prodrug), or a fluorescent dye (profluorophores). In my case and for the work presented
here, the trigger is an enzymatic substrate, namely a quinone propionic acid, and the reporter
group is a fluorescent dye separated by a self-immolative linker. As illustrated in Figure 2.2 the
tripartite probe is stable as long as the enzymatic substrate stays attached. However, chemical or
enzyme initiated cleavage of the trigger group generates an unstable intermediate that breaks
down, allowing the rapid expulsion of the reporter unit.

Figure 2.2

Conceptual view of a tripartite sensor probe and its mechanism of action.

This elegant strategy is a promising approach in the design of biologically–triggered
activation of pro-fluorogenic probes for high-throughput screening or bio−molecular imaging. In
the design of such activatable−probes, careful consideration of the linker functionality is
important in obtaining a faster signal response. A significant amount of research efforts by many
academic groups has been devoted to the study of self-immolative linker systems.2,15 These types
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of linkers contain a latent nucleophilic group that becomes electron-donating either after a
chemical or an enzymatic reaction, subsequently initiating an electron-cascade event that causes
expulsion of the reporter unit.
Out of the many linker systems studied, para-aminobenzyl alcohol (PABA) has received
the most attention in developing self-immolative systems.14 However, I found formation of a
spirolactam16 species hampered the use of PABA spacers in the QPA systems. Thus, a new
strategy was implemented by methylating the amino functionality of PABA, thereby offering a
novel self-immolative linker, N-methyl-p-aminobenzyl alcohol (NMPABA) (Figure 2.3).
(B)
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Figure 2.3
Two different self-immolative tripartite probes having quinone trigger,
N-methyl-p-aminobenzyl alcohol spacer, and nitroaniline reporter groups.
The second portion of this chapter describes the synthesis and kinetics of two different
tripartite probes that incorporate this novel NMPABA linker.
2.2

Experimental

2.2.1

Synthetic Materials and Methods
All chemicals were purchased from Sigma-Aldrich or Fisher Scientific and used as

received. Column chromatography was performed on 50-g SNAP silica columns using a
Flashmaster Personal from Biotage. Thin-layer chromatography was performed on aluminumbacked 60 F254 silica plates from EMD Chemicals Incorporated. 1H and 13C NMR spectra were
collected in CDCl3, DMSO-d6, or methanol-d4 at room temperature on a Bruker AV-400. All
chemical shifts are reported in the standard δ notation of parts per million using tetramethylsilane
as an internal reference. Absorption bands in NMR spectra are listed as singlet (s), doublet (d),
triplet (t), multiplet (m), or two triplets (2t), and coupling constants (J) are reported in hertz (Hz).
Mass spectral analyses were carried out using an Agilent 6210 ESI-TOF mass spectrometer.
Synthesis of compounds are shown in Scheme 2.1 and Scheme 2.2.17-18
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2.2.2

Synthesis
NO2
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1

2
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70% yield
OH

O

(KSO3)2NO

2. Distill

Na2S2O4

H3CO

0.5 M KH2PO4, MeOH, RT

O

H3CO

OCH3

MeOH, RT
O

55% yield
3

91% yield

85% yield

4
O

CH3SO3H, 70 oC

OH
5

O

O

OH

O
PDC

H3CO

H3CO

DMF, RT
OH

O

65% yield

Q3OMe

6

Scheme 2.1

Synthesis of methoxy-substituted quinone propionic acid.17
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Scheme 2.2

Synthesis of para- and ortho- substituted self-immolative tripartite probes.
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2-Methoxy-1,5-dimethyl-3-nitrobenzene (1):
Dimethyl nitrophenol (1.00 g, 5.98 mmol) and methanol (4.00 mL) were heated to 65 oC in an oil
bath. While stirring, 30% aqueous KOH (1.12 mL, 5.98 mmol) was added to the phenolic
solution at 65 °C and stirring continued for 10 min. Dimethyl sulfate (0.57 mL, 5.98 mmol) was
added dropwise to the hot phenolate solution over a 10-min period, and vigorous stirring was
continued for 45 min. The sequential additions of KOH solution and dimethyl sulfate were
repeated four more times using the same amounts and conditions. After the final addition, the
mixture was diluted with water (31 mL) and extracted with ether (4 × 8 mL). The combined ether
extracts were washed with 10% NaOH (3 × 20 mL), 5% HCl (1 × 30 mL), followed by water (1
× 30 mL), and dried over MgSO4. Removal of solvent with a rotary evaporator provided the
nitroanisole as a light brown liquid (0.64 g, 59.6%) which was used in the next step without
further purification. 1H NMR (400 MHz, chloroform-d) δ 7.43 (d, J = 2.2 Hz, 1H), 7.21 (s, 1H),
3.86 (s, 3H), 2.32 (s, 7H).
2-Methoxy-3,5-dimethylbenzenamine (2):
Nitroanisole 1 (3.0 g, 16.56 mmol) in 50 mL of methanol was hydrogenated using a Parr
apparatus at 2-3 atm, with 10% Pd/C (Dry) as catalyst. Hydrogen uptake ceased after 2.25 h and
the mixture was filtered by suction to remove catalyst. Solvent removal with a rotary evaporator
afforded amine as pale yellow liquid (2.28 g, 91%). The amine was used in the next step without
further purification. 1H NMR (400 MHz, chloroform-d) δ 6.44 (d, 2H), 3.74 (s, 5H), 3.48 (s, 1H),
2.23 (d, J = 13.9 Hz, 6H). ESI-MS: for C9H13NO: expected m/z = 151.0997 [M + H]+; found m/z
= 151.0992 [M + H]+; 3.31 ppm error.
2-Methoxy-3,5-dimethylphenol (3):
Aniline 2 (1.4534 g, 0.01 mol) was mixed with ice cold water (26 mL) and a solution of conc.
H2SO4 (2 ml, 0.02 mol) in cold water (10 mL) was added at 0oC with stirring. A solution of
NaNO2 (0.7 g, 0.01 mol) in cold water (10 mL) was added to the amino solution drop wise at 0
o

C. After the addition was complete, stirring was discontinued, the ice bath removed, and the

mixture allowed to stand at room temperature for 2 h. The reaction mixture was distilled for 14
hrs and 450 mL of the distillate was collected. The distillate was extracted with ether (3 x 25 ml),
the combined ether extracts were washed with 60 mL of saturated NaCl, and dried over MgSO4.
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Solvent removal with a rotary evaporator afforded the phenol as a yellow-orange oil (1.06 g,
70%) and was used in the next step without further purification. 1H NMR (400 MHz,
chloroform-d) δ 2.23 (s, 3H), 2.26 (s, 3H), 3.77 (s, 3H), 5.55 (s, 1H), 6.51 (s, 1H), 6.63 (s,
1H). ESI-MS: for C9H12O2: expected m/z = 152.0837 [M + H]+; found m/z = 152.0828 [M + H]+;
5.92 ppm error.
2-Methoxy-3,5-dimethyl-2,5-cyclohexadiene-1,4-dione (4):
Crude phenol 3 (313.7 mg, 2 mmol) was dissolved in 6 ml of methanol and the solution was
placed in a 250 mL round bottom flask. An oxidizing solution was prepared from (1.61 g, 6
mmol) of potassium nitrosodisulfinate (Fremy's salt), 20 mL of 0.5 M KH2PO4 and 80 mL of
water. The oxidizing solution was poured into the phenol solution and the resulting dark purple
solution was stirred at room temperature for 2 h. The mixture was extracted with ether (4 × 20
mL, 3 × 30 mL), and the combined ether extracts were washed with two 80 mL portions of water
then dried over MgSO4. Rotary evaporation gave of the crude quinone, and this was purified on a
25 g/150 mL Flash Si II column using the FlashMaster chromatography system, using ethyl
acetate/dichloromethane/hexane (1:1:2) to give pure quinone as a yellow-orange solid (182.7 mg,
55%). 1H NMR (400 MHz, chloroform-d) δ 6.44 (s, 1H), 4.01 (s, 3H), 2.04 (s, 3H), 1.95 (s, 3H).
ESI-MS: for C9H10O3: expected m/z = 166.0629 [M + H]+; found m/z = 166.0601 [M + H]+; 16.86
ppm error.
2-Methoxy-3,5-dimethyl-1,4-benzenediol (5):
Sodium dithionite (418.25 mg, 2.4 mmol) was dissolved in 6 mL of water and a solution of
quinone 4 (80 mg, 0.48 mmol) in methanol was added at room temperature with stirring. After
stirring for 10 min., the mixture was placed in a separatory funnel and extracted with ether (4 ×
5ml). The combined ether extracts were washed with water (1 × 10ml), brine (1 × 10 mL), and
dried over MgSO4. Solvent removal with a rotary evaporator afforded a quantitative yield of the
crude hydroquinone and this was purified on a 25 g/150 mL Flash Si II column using the
FlashMaster chromatography system using ethyl acetate/dichloromethane/hexane (1:1:2) to give
the pure hydroquinone as a pale yellowish-white solid (367.09 mg, 91%). 1H NMR (400 MHz,
Chloroform-d) δ 6.61 (s, 1H), 5.17 (s, 1H), 4.26 (s, 1H), 3.76 (s, 3H), 2.20 (s, 3H).
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6-Hydroxy-8-methoxy-4,4,5,7-tetramethylhydrocoumarin (6):
Methanesulfonic acid (4 mL) was heated to 70 °C in an oil bath and hydroquinone 5 (287.5 mg,
1.71 mmol) and methyl 3-methyl-2-butenoate (247 µL, 2.02 mmol) were added all at once with
stirring. Stirring was continued at 70 °C for 2.5 h before the reaction mixture was diluted with 40
ml of water and extracted with ether (4 × 20 mL). The combined ether extracts were washed with
40 mL of water, Saturated NaHCO3 (3 × 40 mL), brine (1 × 40 mL), and dried over MgSO4.
Removal of solvent with a rotary evaporator afforded a red-brown oil which was dissolved in 7
ml of 5% ethyl acetate in DCM, and was purified on a 25 g/150 mL Flash Si II column using the
FlashMaster chromatography system using ethyl acetate/dichloromethane (1:20) to remove the
dark impurity, thereby obtaining the pure lactone as a yellow-tan solid (363.55 mg, 85%). 1H
NMR (400 MHz, chloroform-d) δ 5.00 (s, 1H), 3.80 (s, 3H), 2.57 (s, 2H), 2.31 (d, J = 12.0 Hz,
3H), 2.16 (d, J = 8.9 Hz, 3H), 1.45 (s, 6H).
5-Methoxy-β,β,2,4-tetramethyl-3,6-dioxo-1,4-cyclohexadiene-1-propanoic acid (QMeO-COOH):
Lactone 6 (68.65 mg, 0.27 mmol) in 2 ml of DMF was added to a stirred solution of pyridinium
dichromate (464.88 mg, 1.24 mmol) in 7 mL of DMF at room temperature and stirring was
continued for 4 h. The mixture was diluted to 60 mL with water and extracted with ether (3 × 15
mL). The combined ether extracts were washed with 30 mL of water followed by saturated
NaHCO3 (3 × 15 mL). The combined bicarbonate washes were made slightly acidic by the slow
addition of 30% HCl and the resulting aqueous solution was extracted with ether (4 × 15 mL).
The combined organic extracts were washed with 25 mL of brine and dried over MgSO4. Solvent
removal with a rotary evaporator provided a yellow solid which was recrystallized from 20%
chloroform in hexane to afford the pure quinone acid as small yellow needles (46.7 mg, 65%).
1

H NMR (400 MHz, chloroform-d) δ 3.85 (s, 3H), 3.05 (s, 2H), 2.14 (s, 3H), 1.88 (s, 3H), 1.45

(s, 6H). 13C NMR (101 MHz, Chloroform-d) δ 188.41, 186.50, 178.45, 158.04, 150.08, 139.84,
125.40, 59.96, 47.38, 38.36, 29.12, 14.88, 9.01. ESI-MS: for C14H18O5: expected m/z = 266.1154
[M + H]+; found m/z = 266.1130 [M + H]+; 9.02 ppm error.
4-(N-Methylamino)benzyl alcohol (8 para):
To a cold (0 °C) stirred solution of 7 para (10.0 g, 66.1 mmol) in THF (50 mL) was added 1 M
borane-THF complex in THF (200 mL, 200 mmol), dropwise over a period of 1 h. The solution
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was stirred for an additional 5 h at ~25 °C and was then cooled to 0 °C. Then 3 M NaOH (60
mL) was added to the solution to destroy excess hydride and hydrolyze the amine-borane
complex. The heterogenous mixture was stirred for 12 h at ~25 °C. The aqueous phase was
saturated with potassium carbonate, and the organic phase was collected. The aqueous phase was
extracted with Et2O (3 × 50 mL); the combined organic extracts were then dried over anhydrous
Na2SO4. After filtration, the filtrate was rotoevaporated under reduced pressure. The crude
product 8 para (7.60 g, 55.5 mmol in 84 % yield) was used in the next step without further
purification. 1H NMR (400 MHz, methanol-d4) δ 7.22 – 7.01 (m, 2H), 6.69 – 6.48 (m, 2H), 4.44
(s, 2H), 2.73 (s, 3H).
4-((tert-butyldimethylsilyloxy)N-methylamino)benzyl alcohol (9 para):
To a solution of 8-para (5.0 g, 36.45 mmol) in dichloromethane (40 mL) was added tertbutyldimethylsilyl chloride (5.49 g, 36.45 mmol) and imidazole (2.48 g, 36.45 mmol), The
mixture was stirred for 1h at room temperature then the reaction mixture was diluted with brine
solution and then extracted with ethyl acetate (3 × 25 mL). The organic phase was dried over
anhydrous Na2SO4 and filtered. Solvent was removed using a rotary evaporator leaving a light
brown color oil (9.34 g, 37.19 mmol) with 98% yield, which was used without further
purification. 1H-NMR (chloroform-d, 400 MHz) δ 7.18 (d, J = 8.4 Hz, 2H), 6.72 – 6.49 (m, 2H),
4.66 (s, 2H), 2.85 (s, 3H), 0.96 (s, 9H), 0.11 (s, 6H).

13

C-NMR (chloroform-d, 100 MHz) δ

148.51, 130.16, 127.75, 112.27, 65.14, 30.92. 26.06, 18.49, -5.07 ESI-MS: for C14H25NOSi:
expected m/z = 252.1778 [M + H]+; found m/z = 252.1800 [M + H]+; 8.7 ppm error.
3-(3ʹ,6ʹ-Dioxo-1ʹ, 2ʹ,4ʹ-trimethylcyclohexa-1ʹ,4ʹ-dienyl)-3,3-dimethylpropionic acid 4-((tertbutyldimethylsilyloxy)-N-methylamino)benzyl alcohol amide (10-para):
3-(3ʹ,6ʹ-Dioxo-2ʹ,4ʹ dioxo-1′, 2′, 4′-trimethylcyclohexa-1′,4ʹ- dienyl)-3,3 dimethylpropionic acid
Q3 (0.37 g, 1.48 mmol) was dissolved in 50 mL of CH2Cl2, to which was added Nmethylmorpholine (0.45 g, 4.44 mmol). The mixture was cooled to −55 °C. Isobutyl
chloroformate (0.24 g, 1.78 mmol) was then added, followed by addition of 9-para (1.16 g, 2.28
mmol) after 10 min. The reaction mixture was stirred for another 5 h. The residue obtained by
evaporation of the solvent under reduced pressure was dissolved in 50 mL CHCl3. The solution
was then washed with water (60 mL), 5% HCl (60 mL), 5% NaHCO3 (60 mL), and saturated
NaCl (60 mL) solutions. The combined organic extracts were dried over anhydrous Na2SO4 and
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filtered. Solvent was removed using a rotary evaporator, and chromatographed (silica gel, 1:5
EtOAc/Hex) to provide compound 10-para as a yellow-brown solid (0.29 g, 0.61 mmol) with
41 % yield. 1H-NMR (chloroform-d, 400 MHz) δ 7.39 (d, J = 8.0 Hz, 2H), 7.19 – 7.11 (m, 2H),
4.79 (s, 2H), 3.14 (s, 3H), 2.74 (s, 2H), 2.10 (s, 3H), 2.03 – 1.93 (m, 6H), 1.29 (s, 6H), 0.97 (s,
9H), 0.13 (s, 6H). 13C-NMR (chloroform-d, 100 MHz) δ 191.22, 187.69, 172.14, 154.86, 143.65,
142.65, 141.18, 137.69, 136.14, 127.27, 64.41, 47.52, 38.06, 37.10, 28.41, 25.95, 18.43, 14.06,
12.75, 12.11, -5.26. ESI-MS: for C28H41NO4Si: expected m/z = 484.2878 [M + H]+; found m/z =
484.2873 [M + H]+; 1.0 ppm error.
3-(3ʹ,6ʹ-Dioxo-1ʹ, 2ʹ,4ʹ-trimethylcyclohexa-1ʹ,4ʹ-dienyl)-3,3-dimethylpropionic acid 4-(Nmethylamino)benzyl alcohol amide (11-para):
10-para (0.18g, 0.38 mmol) was dissolved in THF (3 mL), to which TBAF (0.6 mL, 1 M in
THF) was added, and subsequently stirred at room temperature for 2 h. Upon completion of the
reaction, the solvent was removed and the residue was dissolved in CH2Cl2, washed with brine,
dried over anhydrous MgSO4, and filtered. Solvent was removed using a rotary evaporator, and
the crude was chromatographed (silica gel, 5:2 EtOAc/Hex) to provide compound 3 as a yellow
solid (0.13 g, 0.35 mmol) with 92 % yield. 1H-NMR (methanol-d4, 400 MHz) δ 7.47 (d, J = 7.9
Hz, 2H), 7.24 (s, 2H), 4.65 (s, 2H), 3.12 (s, 3H), 2.73 (d, J = 5.2 Hz, 2H), 2.07 (s, 3H), 1.96 (d, J
= 9.7 Hz, 6H), 1.27 (s, 6H).

13

C-NMR (methanol-d4, 100 MHz) δ 192.23, 188.76, 174.06,

156.19, 144.70, 144.06, 143.15, 138.89, 137.60, 129.48, 128.46, 64.53, 39.26, 37.51, 30.90,
28.90, 14.33, 12.75, 11.97. ESI-MS: for C22H27NO4: expected m/z = 370.2013 [M + H]+; found
m/z = 370.2001 [M + H]+; 3.24 ppm error.
12-para:
para-nitroaniline isocyanate (19.69 mg, 0.12 mmol) was dissolved in dry THF (1 mL). 11-para
(36.92 mg, 0.1 mmol) and DBTL (6 µL) were added. The reaction was allowed to warm to 45° C
and was stirred for 6 hours. The reaction was monitored by TLC (EtOAc:Hex 1:1). Upon
completion of the reaction, the solvent was removed under reduced pressure, and the crude
product was purified by column chromatography on silica gel (EtOAc:Hex 1:1) to give 12-para
(22.65 mg, 42%) as a yellow solid. 1H NMR (400 MHz, chloroform-d) δ 8.22 (s, 2H), 7.60 (s,
2H), 7.47 (s, 2H), 7.35 (s, 1H), 7.21 (s, 2H), 5.27 (s, 2H), 3.15 (s, 3H), 2.75 (d, J = 5.7 Hz, 2H),
2.10 (s, 3H), 1.96 (d, J = 19.3 Hz, 6H), 1.28 (d, J = 18.9 Hz, 6H).
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13

C NMR (101 MHz,

chloroform-d) δ 191.24, 187.74, 177.27, 172.01, 154.49, 152.56, 144.19, 143.73, 143.20, 137.95,
136.49, 129.77, 125.75, 125.21, 117.85, 66.83, 47.79, 38.10, 33.65, 31.89, 29.58, 28.55, 24.74,
22.67, 14.10, 12.70, 12.70, 12.09. 1H NMR (400 MHz, chloroform-d) δ 6.44 (s, 1H), 4.01 (s,
3H), 2.04 (s, 3H), 1.95 (s, 3H). ESI-MS: for C29H31N3O7: expected m/z = 534.2235 [M + H]+;
found m/z = 534.2240 [M + H]+ ; 0.93 ppm error.
Compounds 8-ortho through 12-ortho were synthesized according to the same procedures
described for 8-para through 12-para.
2-(N-Methylamino)benzyl alcohol (8-ortho): 1H NMR (400 MHz, chloroform-d) δ 7.30 (td, J =
7.8, 1.7 Hz, 1H), 7.05 (dd, J = 7.3, 1.6 Hz, 1H), 6.77 – 6.64 (m, 1H), 4.58 (s, 2H), 2.87 (s, 3H).
13

C NMR (101 MHz, chloroform-d) δ 148.50, 129.65, 128.99, 124.57, 116.56, 110.27, 64.36,

30.40.
2-((tert-Butyldimethylsilyloxy)-N-methylamino)benzyl alcohol (9-ortho): 1H NMR (400 MHz,
chloroform-d) δ 7.26 (td, J = 7.9, 1.6 Hz, 1H), 7.12 – 7.01 (m, 1H), 6.75 – 6.62 (m, 2H), 4.72 (s,
2H), 2.90 (s, 3H), 0.94 (s, 12H), 0.10 (s, 6H).

13

C NMR (101 MHz, chloroform-d) δ 148.89,

129.11, 128.21, 124.86, 116.29, 109.88, 65.49, 30.33, 25.94, 18.28, -5.12.
3-(3ʹ,6ʹ-Dioxo-1ʹ,2ʹ,4ʹ-trimethylcyclohexa-1ʹ,4ʹ-dienyl)-3,3-dimethylpropionic

acid

2-((tert-

butyldimethylsilyloxy)-N-methylamino)benzyl alcohol amide (10-ortho): 1H NMR (400 MHz,
chloroform-d) δ 7.68 – 7.61 (m, 1H), 7.38 (dd, J = 29.9, 7.5, 1.5 Hz, 2H), 7.11 (dd, J = 7.7, 1.4
Hz, 1H), 4.74 (d, J = 13.8 Hz, 1H), 4.69 – 4.59 (m, 1H), 3.07 (s, 3H), 2.65 (d, J = 17.1 Hz, 1H),
2.56 (d, J = 17.0 Hz, 1H), 2.10 (s, 3H), 2.02 – 1.92 (m, 6H), 1.28 (d, J = 14.5 Hz, 6H), 0.99 (s,
12H), 0.14 (s, 6H).

13

C NMR (101 MHz, chloroform-d) δ 191.20, 187.72, 172.17, 154.81,

143.56, 140.42, 137.72, 138.04, 128.65, 128.48, 127.99, 60.86, 47.89, 37.67, 36.17, 28.53, 18.42,
14.10, 12.76, 12.10, -5.32
3-(3ʹ,6ʹ-Dioxo-1ʹ,2ʹ,4ʹ-trimethylcyclohexa-1ʹ,4ʹ-dienyl)-3,3-dimethylpropionic

acid

4-(N-

methylamino)benzyl alcohol amide (11-ortho): 1H NMR (400 MHz, methanol-d4) δ 7.68 – 7.60
(m, 1H), 7.44 (dtd, J = 16.9, 7.4, 1.7 Hz, 2H), 7.20 (dd, J = 7.4, 1.6 Hz, 1H), 4.57 (q, J = 13.3
Hz, 2H), 3.07 (s, 3H), 2.69 (d, J = 17.2 Hz, 1H), 2.59 (d, J = 17.2 Hz, 1H), 2.08 (s, 3H), 2.04 –
1.93 (m, 6H), 1.28 (d, J = 4.4 Hz, 6H).

13

C NMR (101 MHz, methanol-d4) δ 192.24, 188.65,
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174.09, 156.22, 144.57, 142.26, 39.82, 138.84, 137.37, 130.43, 130.07, 130.00, 129.27, 60.83,
38.86, 36.97, 28.90, 28.76, 14.40, 12.79, 12.03.
12-ortho: 1H NMR (400 MHz, chloroform-d) δ 9.00 (s, 1H), 8.23 – 8.12 (m, 2H), 7.73 – 7.55 (m,
3H), 7.47 (dtd, J = 27.0, 7.5, 1.6 Hz, 2H), 7.26 – 7.13 (m, 1H), 5.48 (d, J = 12.1 Hz, 1H), 4.83 (d,
J = 12.0 Hz, 1H), 3.18 (s, 3H), 2.21 – 2.06 (m, 3H), 2.00 – 1.91 (m, 6H), 1.53 – 1.37 (m, 3H),
1.21 (s, 3H).

13

C NMR (101 MHz, chloroform-d) δ 192.85, 187.29, 172.61, 155.01, 152.76,

144.63, 143.40, 142.87, 138.45, 136.23, 132.75, 131.09, 129.05, 125.12, 117.71, 63.72, 47.63,
37.70, 36.31, 28.74, 27.71, 14.12, 12.79, 12.16.
2.3

Results

2.3.1

Synthesis of QMeO-COOH
QMeO-COOH (Figure 2.4) was synthesized according to Scheme 2.119-20 as a part of an

on-going project in the McCarley group that involves the development of redox-active trigger
groups. The first step of the synthesis involves methylation of o-hydroxyl group dimethyl
nitroaniline by the excess addition (1:3 mol) of dimethylsulfate to form 1.
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Figure 2.4

Crystal structure of QMeO-COOH.
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Then the nitro group of 1 was reduced to amine 2 by catalytic hydrogenation using a Parr
apparatus. The amine of 2 was then converted to phenol 3 by diazotization, followed by
hydrolysis. Then oxidation of 3 by Fremy’s salt, gave the benzoquinone 4, which was reduced to
the corresponding hydroquinone 5 using sodium dithionite. The next step involved 1,4-Michael
addition of methyl 3-methyl-2-butenoate to the hydroquinone 5, giving the lactone 6. Finally the
PDC oxidation of lactone 6 yielded the target mono-methoxy quinone propionic acid QMeOCOOH.
2.3.2. Faster signal relay over self-immolation
The tripartite probes (A, B) were designed, such that the nitroaniline reporter groups on
the benzylic substituents are located at the para and ortho positions of the corresponding methyl
aniline group. The amide linkage with the quinone propionic acid (QPA) masks the functionality
of the methyl aniline group. Removal of the QPA group by chemical means resulted in
disruption of probe molecular structure, so as to cause release of the reporter, para-nitroaniline
either by elimination of a para- or ortho- azaquinone–methide species (Scheme 2.3).
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Scheme 2.3 Proposed self-immolative removal of the nitroaniline reporter groups by 1,6- and
1,4-elimination pathways.
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According to the proposed general mechanism for reporter elimination (Scheme 2.3),
initial reduction of the quinone to a hydroquinone is followed by the formation of an unstable
tetrahedral intermediate. This intermediate then collapses to form a lactone and an unmasked
methyl aniline moiety, thereby triggering the self-immolative process. Disassembly through selfimmolation either by 1,4- or 1,6-elimination results in the release of the nitroaniline reporter
groups. However, such an elimination process does not lead directly to the release of the
reporter. Instead it produces an unstable carbamic acid intermediate, which rapidly breaksdown
to form the free reporter and carbon dioxide at pH = 7.4.21 This dual elimination entropically
drives the reaction in the forward direction.
The UV-vis absorbance spectra of the two tripartite probes showed two distinct bands,
one around 250 nm and another around 327 nm (Figure 2.5). To assess kinetics of 1,6- and 1,4self-immolation, solutions of probes A and B were incubated with two equivalents of a strong
reducing agent, sodium dithionite (Na2S2O4), and their absorbance was monitored for one hour.
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Figure 2.5
UV-vis absorbance spectra of 40 µM A (1), and 40 µM B (2) upon addition of
Na2S2O4 (2 eq) in 1:1 DMSO:PBS pH = 7.4 buffer. Solid line – before dithionite addition, and
dashed – 1 h after dithionite addition. The arrow pointing downwards represents the decrease in
intensity of the 327 nm band, and the upward arrow represents the increase in intensity of the
391 nm band.
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The result showed that the band at 327 nm decreased with a concomitant increase of a
band around 391 nm. The latter corresponds to the release of the nitroaniline group that showed
gradual increase over the time period studied.
2.3.3

Kinetics of 1,6- and 1,4- self-immolation routes
Upon addition of the reducing agent dithionite, the disappearance of the reactant probes

A and B (at 327 nm), and the appearance of the product nitroaniline (at 391 nm) were followed
continuously by UV-vis spectroscopy (Figure 2.6 (a) and (b)). It is important to note that in the
graphs depicted in Figure 2.6, the extent of the reaction refers to the complete product formation
(at 327 nm) or the reactant disappearance (at 391 nm) for the maximum time studied. The
nitroaniline product formation and the para-quinone methide disappearance was observed in
roughly 1 hour, and it took roughly more than two hours for ortho-quinone disappearance. These
results indicate that both the rates of the reactant disappearance and the product formation for A
are faster than that of B.
2.4

Discussion
The kinetic experiment revealed vastly different kinetic profiles for compounds A and B

that have similar electronic arrangement for their self-immolative behavior. As evidenced by the
UV-vis kinetic data, the 1,6-elimination from A is faster compared to the 1,4-elimination from B
(Figure 2.6). This is in agreement with some previous work done by other academic groups with
different self-immolative systems.2,14,22-23 In contrast, Lee et al. reported a more rapid 1,4elimination over the more common 1,6-elimination route with hydroxycoumarin based triggerlinker-reporter conjugates.15
2.4.1

Kinetic rate equation for the overall rate
According to the proposed overall mechanism (Scheme 2.4), the initial rate of reduction

of the tripartite probe activation should be virtually identical for both A and B, because dithionite
is a strong reducing agent. Previous studies in the McCarley group with a wide range of
substituted quinone propionic acid groups revealed that dithionite reduction of the quinone
propionic acid head group to a reduced hydroquinone group is fast and complete within 1s.
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a)

b)

d)

c)

Figure 2.6
Plot of extent of reaction vs time a) [R]/[R]0 (Reactant disappearance) and b)
[P]/[P]∞ (Product formation); c) and d) Plot of ln(extent of reaction) vs time for ortho- (purple)
and para- (yellow) probes. Also a) and c) represent the reactant disappearance and b) and d)
represent the product formation. The linear region, showing first-order kinetics, is marked with a
green box.
Therefore, it is safe to assume that the initial reduction step has little to no impact on the
overall rate of the reaction. Further previous work by Johnson et al. demonstrated carbamic
species of N-arylcarbamates have short lifetimes,21 therefore it is possible that the
decarboxylation step depicted in Box 2 to have similar rate (k4) for both ortho- and paraspecies, thus not providing sufficient contribution to the rate change of the two species.
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Scheme 2.4 Proposed detailed overall reaction steps associated with the 4-nitroaniline
production from para- (A) and ortho- (B) tripartite probes. Box 1 – possible reaction steps
involved in the rate determining step (RDS) for Reactant: hydroquinone (R), Tetrahedral
Intermediate (I), and Products: lactone and linker+nitroaniline species (P%%); inset, simplified
overall reaction equations. Box 2 – decarboxylation yielding 4-nitroaniline.
Earlier work by Milstein et al.24 and later by Danforth et al.25 proved that the rate
determining step in the lactonization reaction is breakdown of the tetrahedral intermediate, and
that it could be governed by steric factors. According to Scheme 2.4, three steps can be
influenced by steric factors, namely 1) rate of formation of the tetrahedral intermediate (k1[R]),
2) rate of collapse of the tetrahedral intermediate (k2[I]), and 3) rate of quinone methide
formation (k3[P%%]). The obtained crystal structures for 11-para and 11-ortho (Figure 2.7) exhibit
a difference in the geometry of the two systems. Assuming that the nitroaniline attachment does
not alter the overall geometry of A and B, attack of O1 to C9 (Figure 2.7) for formation of the
tetrahedral intermediate is more feasible for the less sterically hindered 11-para over the more
sterically congested 11-ortho. Winans et al. suggested that the rate of the lactone formation is
largely governed by the relief of strain of the tetrahedral intermediate.26 If this holds true one
shall expect that the more strained ortho to collapse faster in comparison to para. Therefore it
could be argued that the slowest step could be the formation of the tetrahedral intermediate and

69

11-ortho

11-para

Figure 2.7

Single crystal X-ray structures of 11-para and 11-ortho.

not the collapse of it. Further, it is also important to account for the steric factors involved in the
rate (k3[P%%]) of the quinone methide formation step, and the UV-vis data does not provide
adequate information to distinguish the rate-determining step between them.
Considering that concentration of the tetrahedral intermediate (I) does not build up at
appreciable amount and is less stable than either of the reactant (R) and products (P) during the
course of the reaction the concentration of I will be low, consequently I will reach a steady state.
d [ R]
= k1 [ R ] − k−1 [ I ]
dt
d [I ]
= k1 [ R ] − k−1 [ I ] − k2 [ I ]
dt

−

From a steady state approximation of [I],

[I ]ss =

Equation (1)

d [I ]
=0
dt

k1[R]
k−1 + k2

Equation (2)
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−

d [ R ] k1
=
k2 [ R ] = K eq k2 [ R ]
dt
k−1

Equation (3)

However, prior to reaching steady state of [I], rate of reactant disappearance depends on
both [R] and [I]. But [I] is affected by reactions forming it/removing it. So, it would appear that
the para species forms product very fast prior to the steady state of [I] being reached, after which
the rate slows down. Possibly conversion of R to I is initially fast, then the collapse is slow. Also
for the ortho case, products are formed slowly at first until the steady state of [I] is reached, then
the rate is faster. Perhaps initial rate reflects tetrahedral intermediate (I) formation, then change
in rate reflects fast collapse of I. These arguments are in agreement with the sterics of I formation
(ortho slower vs para). However, it is also important to note that the rate of P%% formation is
k2[I]ss, so it is hard to compare para and ortho collapse rates.
Interestingly, the plot of the ln(extent of the reaction) vs time exhibited a linear
dependence on time for the disappearance of the reactant (327 nm band) for both the ortho- and
para- trigger probes (Figure 2.6 c) for select time periods, denoted by green highlighting. As
shown in Figure 2.8 the carbamate linkage in the nitroaniline reporter appears to be responsible
for the chromophore that displays an absorbance band around 327 nm. Further support for this
comes from the UV-visible spectra of p-nitroacetamide (NIST database)27 species with a
absorption maxima similar to what I observed for the para species. Therefore the decrease in
intensity of the 327 nm absorption band (reactant disappearance) could be associated with k1, k2,
and k3 steps. However, the data obtained is not sufficient to show the chromophore associated
with linker+nitroaniline conjugate (k3 step) plays a role in the disappearance of the 327 nm
absorption band. Nevertheless, the linear dependency of the decreasing 327 nm absorption band
could provide an observed rate constant (Equation 4) to account for the rate change in 1,4(ortho-) and 1,6-elimination (para-) pathways. From Equation (3) at steady state,

[ R] = [ R]0 e−k (obs)t
ln

[R]
= −kobs t
[R]0
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Equation (4)

O
NH

O2N

N

O

O
O
O

O2N

O
N

NH2

O

HO

O

Figure 2.8
The absorbance spectra of the para probe A (red), nitroaniline reporter (green),
and QPA+para-linker (blue) in 1:1 DMSO:PBS pH = 7.4 buffer.
Therefore, in order to calculate the observed pseudo first-order rate constant (based on
Equation 4), the slope of the curve marked with a green box in ln (“extent of the reaction”) plot
(Figure 2.6 c) was used, omitting the time that showed non-linear dependence. The observed rate
constant (kobs,) for nitroaniline release through 1,6 elimination from para-quinone was found to
be 0.075 min−1, and for 1,4 elimination from ortho- quinone to be 0.029 min−1 (Figure 2.9). Thus
a 2.6-fold change in rate provides evidence for the observed faster kinetics for para- over orthotripartite probe. However, the same trend was not observed in plots Figure 2.6 (b) and (d),
suggesting mixed kinetics for the nitroaniline formation step.
Steric analysis based on the single-crystal structures may oversimplify the reasoning for
these different outcomes, and more work is needed in order to truly understand the kinetics of the
self-immolative behavior of these probes. For example, geometry optimization with
computational methods (including solvent parameters) would be useful for better understanding
the steric factors in aqueous media, or replacing the quinone trigger with a Boc protecting group
would eliminate the possibility of tetrahedral intermediate formation to give the true kinetics of
the 1,6- and 1,4-self-immolation. However, the kinetic experiments carried out have shown that
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a)

b)

Figure 2.9
Linear region of the ln(extent of the reaction) vs time plots showing first-order
kinetics for a) para- and b) ortho-trigger probes.
the novel NMPABA spacer (with 1,6-elimination pathway) has a favorable rate of elimination
such that the spacer is appropriate for use in the design of profluorogenic imaging probes. In
addition the enzyme recognition unit can be separated from a hydrophobic fluorophore to
achieve improved chemical stability and enzymatic reactivity in the detection and imaging of
cancer cell lines. The use of this novel self-immolative spacer, in the development of an enzymeactivatable probe and its evaluation in cancer cell lines is discussed in the following chapter.
2.5
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CHAPTER 3
DESIGN, SYNTHESIS, AND EVALUATION OF A PET-MODULATED
NAPHTHALIMIDE-BASED SELF-IMMOLATIVE PROFLUOROPHORE
3.1

Introduction
The design and optimization of new enzymatically–triggered, fluorescence–based probes

specific to biological agents holds great potential in the emerging and promising field of biomolecular imaging and bio-marker quantification.1-3 Development of such probes with biological
activity and signatures will define the borders of diseased and healthy tissue during fluorescenceassisted surgical resection of cancerous tissues and collection of real-time information on
diseased tissue cell micro-environment.4-6 To attain this potential, it is necessary to build a
diverse base of disease–associated, enzyme–activatable probes.
Development of activatable–probes7-8 with superior signal-to-background-ratios (SBR),7,9
defined as the amount of signal in the region of interest relative to the amount of signal in a
neighboring region,10 require either (1) a maximal signal from the target, (2) a minimal signal
from the background, or (3) a combination of the two. In this regard, triggered-activation of
imaging probes offers distinct benefits over their “always-on”7,11 counterparts, specifically by
providing high SBR, which is critical in identifying small cancer foci or creating highly defined
boundaries that clearly demark the cancer cells from the surrounding normal healthy cells. In this
route, the probes are designed in such a way that the fluorescence response is switched-on only
by highly sensitive and selective removal of a fluorescence quencher from the probe by
triggered-activation to generate a high fluorescent reporter. Since these probes are fluorescently
quenched (or “off”) at the beginning and retain fluorescence only after activation (or “on”), a
high SBR can be achieved despite the presence of unactivated probe remaining in circulation.
This is a clear advantage over the “always-on” probes, whose fast clearance is essential for high
SBR.
Numerous imaging probes that exploit targets associated with cancer cells (e.g. pH, pO2,
oxidation, enzymes) for probe activation have been designed. However, only a small number of
12

This chapter reprinted with permission from Hettiarachchi, S.U.; Prasai, B.; McCarley, R.L.;
J. Am. Chem. Soc, 2014, 136, 7575-7578. Copyright (2014) American Chemical Society.
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imaging probes have the ability to selectively and rapidly reveal their fluorescence in the
presence of a cancer-associated enzyme as is the type of disease-associated activating enzymes.12
To date, only three distinct cancer-linked enzymes have been targeted for unmasking of probe
fluorescence with improved SBR.6,13-14 Common methods used to quench a probe’s fluorescence
include: fluorescence resonance energy transfer (FRET), photo-induced electron-transfer (PeT),
and internal-charge-transfer (ICT), whereby the reporter’s fluorescence is restored by enzymeinitiated removal of the FRET quencher/donor pair or reaction specific cleavage of the quencher
(trigger group) from the probe.12
NAD(P)H:quinone oxidoreductase-1 (NQO1, DT-diaphorase, EC 1.6.99.2)15-16 is a
chemoprotective enzyme, and its overexpression (2- to 50-fold greater than normal tissue) is
found in a wide variety of human tumor cells (e.g., colon, breast, pancreas, non-small cell lung)15
making it a prime target for the design of bio-activatable profluorophores and prodrugs.17-18 A
distinct feature of this endogenous, cytosolic cancer-associated enzyme is its ability to catalyze a
direct two-electron reduction of quinone to hydroquinones. This substrate specificity for
quinones was utilized in the design of imaging probes for NQO1 detection. This approach to an
enzyme-specific turn-on fluorescence probe relied on the tuning of a push-pull internal charge–
transfer (ICT)19 within the naphthalimide scaffold to change its emission properties by a redoxmediated reaction.
The work here is concerned with the design and synthesis of a molecular probe consisting
of a trigger recognition unit, a linker and a fluorophore. The probe is efficiently quenched via
PeT process, by it being bound to an activatable trigger group coupled to the naphthalimide
through a novel self-immolative linker.20-21 The highly selective and rapid activation of the
trigger group is achieved by chemical and enzymatic (NQO1-specific) means that result in
activation of the trigger group’s detachment from the self-immolative linker, with the latter subsequently cleaved from the reporter autonomously, thereby unmasking intense, red-shifted
fluorescence emission. To achieve this result, I used a trimethyl-locked quinone propionic acid
trigger group and an N-methyl-p-aminobenzyl alcohol self-immolative linker attached to the
reporter (Figure 3.1).21-22 Delineated here are the synthesis and characterization of this cloaked
fluorophore and the evaluation of its triggered turning on in the presence of NQO1.
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3.2

Experimental

3.2.1

Synthetic material and methods
All chemicals were purchased from Sigma-Aldrich or Fisher Scientific and used as

received. Column chromatography was performed on 50-g SNAP silica columns using a
Flashmaster Personal from Biotage. Thin layer chromatography was performed on aluminumbacked 60 F254 silica plates from EMD Chemicals Incorporated. 1H and 13C NMR spectra were
collected in CDCl3, DMSO-d6, or methanol-d4 at room temperature on a Bruker AV-400. All
chemical shifts are reported in the standard δ notation of parts per million using tetramethylsilane
as an internal reference. Absorption bands in NMR spectra are listed as singlet (s), doublet (d),
triplet (t), multiplet (m), or two triplets (2t), and coupling constants (J) are reported in hertz (Hz).
Mass spectral analyses were carried out using an Agilent 6210 ESI-TOF mass spectrometer.12
3.2.2

Synthesis
The general methods for all synthetically derived compounds are shown in Scheme 3.1

and Scheme 3.2. 3-(3',6'-dioxo-2',4',5'-trimethylcyclohexa-1',4'-diene)-3,3-dimethylpropionic
acid

(Q3PA,

5),

4-(N-methylamino)benzyl

alcohol

(7),

and

4-amino-9-(n-butyl)-1,8-

naphthalimide (Nap) were synthesized according to literature procedures.23
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4-Amino-9-(n-butyl)-1,8-naphthalimide (Nap)
4-Amino-1, 8-naphthalic anhydride (1.14 g, 4.6 mmol) was dissolved in 250 mL ethanol under
nitrogen atmosphere and brought to reflux. Then butylamine (2.0 mL, 20.23 mmol) was added
and refluxed for 14hrs. After cooling the solvent was removed under reduced pressure and the
crude was purified in flash column (20:1 DCM: EtOAc) to get the product as a yellow solid in
75% Yield. 1H NMR (400 MHz, DMSO-d6) δ 8.61 (d, J = 8.4 Hz, 1H), 8.43 (d, J = 7.3 Hz, 1H),
8.24 – 8.13 (m, 1H), 7.66 (t, J = 7.9 Hz, 1H), 7.43 (s, 2H), 6.85 (d, J = 8.6 Hz, 1H), 4.01 (t, J =
7.5 Hz, 2H), 1.58 (p, J = 7.5 Hz, 2H), 1.33 (h, J = 7.7 Hz, 2H), 0.95 – 0.89 (m, 3H). 13C NMR
(126 MHz, DMSO-d6) δ 14.22, 20.30, 30.31, 108.04, 108.62, 119.83, 122.27, 124.45, 129.73,
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130.14, 131.45, 134.40, 153.14, 163.36, 164.23. ESI-MS: for C16H16 N2O2: expected m/z =
269.1292 [M+H] +; found m/z = 269.1288 [M+H] +; 1.5 ppm error.
Q3Nap:
To a mixture of compound 2 (54 mg, 0.2 mmol) and DMAP (49 mg, 0.4 mmol) in 10 mL
CH2Cl2 was added a solution of phosgene (15% in toluene, 1.0 mL) at −10 °C. The resulting
solution was stirred for 3 h maintaining at −10 °C under argon. The excess phosgene was then
removed by bubbling argon gas for 30 min. To this solution was added the alcohol 3 (221 mg,
0.6 mmol) and the solution was stirred at 0 °C overnight. The reaction mixture was quenched
with water (10 mL), and extracted with CH2Cl2 (2×25 mL). The organic phase was dried over
Na2SO4 and then filtered. Solvent was removed using a rotary evaporator and the crude material
was chromatographed (silica gel, 5:1 CH2Cl2/EtOAc) to provide Q3Nap as a yellow solid (41.10
mg, 0.06 mmol, 31 % yield). 1H-NMR (Chloroform-d, 400 MHz) δ 8.63 (t, J = 8.4, 2.2 Hz, 2H),
8.41 (d, J = 8.3 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 7.78 (t, J = 8.8, 8.2, 2.3 Hz, 1H), 7.57 – 7.48
(m, 2H), 7.26 (d, J = 7.5 Hz, 2H), 5.35 (s, 2H), 4.22 – 4.07 (m, 2H), 3.17 (s, 3H), 2.77 (s, 2H),
2.10 (d, J = 2.4 Hz, 3H), 2.07 – 1.94 (m, 6H), 1.78 – 1.65 (m, 2H), 1.44 (q, J = 7.8, 3.7 Hz, 2H),
1.34 – 1.21 (m, 6H), 0.98 (t, J = 7.4, 2.3 Hz, 3H). 13C-NMR (Chloroform-d, 100 MHz) δ 191.45,
187.79, 172.1, 164.23, 163.76, 154.66, 153.03, 144.45, 138.71, 136.58, 132.6, 131.42, 130.12,
129.1, 127.98, 126.87, 125.76, 123.77, 123.05, 118.34, 116.99, 67.3, 47.94, 40.42, 38.23, 37.27,
30.37, 28.68, 20.54, 14.27, 14.00, 12.89, 12.30. ESI-MS: for C39H41N3O7: expected m/z =
664.3018 [M + H]+; found m/z = 664.3030 [M + H]+; 1.8 ppm error.
1-(Carbamoylmethyl)-3-carbamoylpyridinium iodide (13)
A mixture of nicotinamide (1.0g, 8.2 mmol) and 2-iodoacetamide (1.5g, 8.2 mmol) in DMF was
stirred at 60 °C for 4 hours. After cooling to room temperature, the mixture was diluted with
ethyl acetate and stirred for another 30 minutes. Filtration and recrystallization from aqueous
ethanol afforded colorless crystals. 1H NMR (400 MHz, methanol-d4) δ 9.40 (s, 1H), 9.10 (s,
2H), 8.37 (s, 1H), 5.72 (s, 2H).24
1-Carbamoylmethyl-3-carbamoyl-1,4- dihydropyridine (14)
To a solution of (20 mg) in water (5 mL) was added anhydrous sodium carbonate (50 mg),
sodium bicarbonate (50 mg), and sodium hydrosulfite (50 mg), and stirred for 30 min at 37 °C.
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Solvent was evaporated, and the residue obtained was dissolved in methanol. Purification with
C-18 RP column through a gradient elution (0—50%) AcCN in water afforded. 1H NMR (400
MHz, methanol-d4) δ 7.05 (s, 1H), 5.94 (s, 1H), 5.04 (s, 1H), 4.06 (s, 1H), 3.16 (s, 2H).24
3.2.3

Cyclic voltammetry
Cyclic voltammetry was performed on Q3Nap in 0.1 M (n-butyl)4NClO4/dry acetonitrile

under anaerobic conditions. A Princeton Applied Research Potentiostat/Galvanostat Model 273A
was used along with the program Power Suite-2.53. Voltammograms were collected at 0.1 V s−1
at room temperature after degassing the solution with nitrogen for 20 min. Glassy-carbon
working (BAS, 3-mm diameter), platinum wire counter, and Ag/AgCl reference (BAS)
electrodes were used, and the potentials were referenced versus ferrocene/ferrocenium internal
standard.12
3.2.4

Enzyme kinetics
hNQO1. All fluorescence measurements (λex = 432 nm, λem = 540 nm) were obtained at

room temperature with solutions composed of pH 7.4, 0.1 M PBS/0.1 M KCl/0.007% BSA.
Solutions of β-nicotinamide adenine dinucleotide, reduced disodium salt (NADH, SigmaAldrich) were made with the PBS buffer so that subsequently prepared solutions possessed a
final concentration of 1 × 10−4 M β-NADH in each assay. Solutions consisting of 2 × 10−6 to 6 ×
10−5 M Q3Nap were made using the NADH stock. A 40 µg mL-1 stock solution of recombinant
hNQO1 (Sigma-Aldrich) was prepared using the same buffer as above so as to give 4.0 × 10−5 g
hNQO1 per assay. Each assay was performed in a quartz fluorescence cuvette containing 1 mL
Q3Nap solution and initiated by the addition of 1 mL hNQO1 solution. Measurements were
collected every 30 s for 10 min. Fluorescence units were converted to concentration by relating
the signal increase to a fluorescence signal derived from a known concentration of Nap reporter.
Plots of velocity versus Q3Nap concentration were used to obtain apparent Km and Vmax values
from nonlinear least-squares analysis employing algorithms developed by Cleland for
Michaelis−Menten kinetics.12
hNQO2. The fluorescence (λex = 432 nm, λem = 540 nm) at room temperature was
recorded versus time for solutions of 40 µg mL-1 recombinant hNQO2 (Sigma-Aldrich),
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5 × 10−5 M Q3Nap, and 1 × 10−4 M co-substrate in pH 7.4, 0.1 M PBS/0.1 M KCl/0.007% BSA.
Co-substrate for hNQO2 was prepared according to Richard J. Knox et al.24
3.2.5

Cell culture: This work was performed by Bijeta Prasai in the McCarley research group
HT29 (human colorectal adenocarcinoma), H596 (human non-small cell lung cancer),

cell culture base media, and fetal bovine serum (FBS) were purchased from American Type Cell
Culture (ATCC), Manassas, VA. Cell culture was performed as suggested by ATCC. HT29 cells
were cultured in McCoy’s 5A base medium supplemented with 10% FBS and 100 IU/ml
penicillin-streptomycin (purchased from Invitrogen). H596 cells were cultured in RPMI-1640
with 10% FBS and 100 IU/ml penicillin-streptomycin. Cells were incubated at 37 °C in a
humidified incubator containing 5% wt/vol CO2.
3.2.6

Cell imaging via scanning laser confocal microscopy and wide-field microscopy
HT29 and H446 cells were cultured overnight in 22 × 22 mm glass coverslips on a treated

tissue culture 6-well plate purchased from Fisher Scientific. At that time, old growth medium
was replaced with 2 mL of fresh medium and then incubated at 37 °C. Solutions of Q3Nap
prepared in DMSO were added to each cell line to give 2 × 10−5 M solution of Q3Nap, keeping
the DMSO concentration at 1% or less. Cells were incubated with Q3Nap at 37 °C for 30 min
(HT29) and 2 h (H596). Cells were then treated with 3.0 × 10−6 M DRAQ5 (nuclear stain
obtained from Thermo Scientific) for 1 min. Then the medium was removed, and the cells were
fixed in 2 mL of 4% paraformaldehyde for 15 min with shaking. After fixing, the cells were
rinsed with Nanopure water, and the coverslips were mounted to glass slides with Immumount
(obtained from Fisher Scientific). Glass slides were left in the dark overnight to allow the
Immumount to dry. Confocal images were acquired using a Leica TCS SP2 spectral confocal
microscope. For images of cells exposed to Q3Nap, samples were excited using the 458-nm line
of an Ar/KrAr laser, and the spectral emission was collected between 458 and 514/514 and 680
nm (Leica DD458/514). Likewise, cells exposed to DRAQ5 were excited using the 633-nm line
of a HeNe laser, and the spectral emission was collected between 678 and 773 nm. All images
were collected using a pinhole of 3.1 Airy units. Images were frame and line averaged 4 times.
Image analysis was performed using ImageJ and Leica LAS AF lite software. Wide-field images
were acquired using a Leica DM RXA2 fluorescent microscope equipped with a 100x 1.4NA
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objective lens and a Cooke SensiCam QE. Slidebook software was used to control the camera
and microscope as well as image renormalization, deconvolution and scale bar placement. The
nucleus was stained with DRAQ5, and a Leica CY5 filter set (λex = 590–650 nm, λem = 663–737
nm) was used when visualizing this dye. Cells exposed to Q3Nap were examined using a CFP
filter set (λex = 426–466 nm, λem = 460–500 nm).
3.3

Results and Discussion

3.3.1

Spectroscopic properties of Q3Nap and Nap
Spectroscopic properties of the probe Q3Nap and the free dye Nap showed striking

differences in buffered aqueous media (Figure 3.2 (a) and (b)). The probe Q3Nap showed a broad
absorption band centered around 380 nm with an extinction coefficient (ε = 2.1 x 104 M−1cm−1)
while Nap reporter had a broad absorption band centered around 432 nm with an extinction
coefficient (ε = 1.9 x 104 M−1cm−1).
These differences are attributed to the presence of the quinone propionic acid trigger
group (Q3PA), as well as the carbamate connection between the N-methyl-p-aminobenzyl
alcohol, NMPABA, linker, and the naphthalimide fluorophore. The NMPABA linker imparts
several different inherent properties for the Q3Nap probe system; (1) the self-immolative
behavior provides a faster signal relay upon a trigger event, (2) the tertiary amide provides
enhanced environmental stability (prevents the formation of the spirolactam species), (3) the
aromatic nature and short linker length allow for a high probability of electron transfer that
yields a favorable ΔGPeT, and 4) forms a carbamate linkage with the Nap dye effecting its ICT
push-pull properties. The λreport is red shifted roughly 50 nm in comparison to λprobe (432 nm vs
380 nm), as is λreport vs λprobe (532 nm vs 480 nm), with both observations being in accord with
the presence of the electron-deficient carbamate in Q3Nap. Another important feature of the
probe system is the absorptivity of Q3Nap at the maximum absorption wavelength of Nap is ∼5
times lower than that for Nap reporter. A combination of the aforementioned factors help Q3Nap
probe to achieve high signal-to-background ratios.
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Figure 3.2
Absorption and emission spectra of 2 × 10−6 M a) Q3Nap and b) reporter Nap in
pH 7.40, 0.1 M phosphate buffer; T = 25 °C.12
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3.3.2 Thermodynamic feasibility of PeT quenching
In order to assess the thermodynamic feasibility and efficiency of this novel fluorescence
quenching of Q3Nap by oxidative electron transfer (OeT) and by reductive electron transfer
(ReT),25 as depicted in Figure 3.3, outcomes from voltammetricArticle
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i(A)

quinone to
trigger to
andextant
the Napbutyl
reporterreporters
were used
the Rehm-Weller
naphthalimide
thatin are
quenched by equation to calculate
n reduction of quinones
22
reductive
electron-transfer
(ReT).
The
Rehm−Weller
equa-potential (E ) of the
enzyme an idealthe
target
for
energy of the PeT process, Equation 1. For the OeT process, the redox
D
tion, eq 1,
phores.
operties, and NQO1-speciﬁc
e2
ation, PeT-quenched ﬂuoΔG PeT = E D − EA − ΔG00 −
Equation 1
(1)
εd
or probe readily penetrates
ls because it is hydrophobic,
was used to examine possible quinone propionic acid
rge neutral. Upon rapid and
quenchers24 and 1,8-naphthalimide reporters as well as linkers
n of the quinone quencher
-5
between
the OeT quencher and the NI reporter, so as to ensure
3.0x10
an intensely light-emissive
that quenching is thermodynamically feasible and eﬃcient.15 In
s removal of the activated 2.0x10
this-5 equation, ED is the redox potential of the donor and EA that
quenching of ﬂuorescence
of the acceptor, ΔG00 is the energy of the ﬁrst excited singlet
-5
ured by careful selection of 1.0x10
state
of the reporter, and e2/εd is the Coulombic interaction
naphthalimide reporter and
energy of the ion pair, known to be 0.06 eV.15 The energy of
highly ﬂuorescent, cationic
0.0 ﬁrst excited singlet state of NI was measured to be 3.06
the
exhibits a strong Stokes shift
eV.-515 From voltammetric measurements, ED of NI was
cence emission maxima due -1.0x10
determined to be 1.74 V, and EA for the quinone propionic
ansfer mechanism associated
acid
group of Q 3NI was found to be −1.01 V (Figure S2).
-5
erall, these probe character- -2.0x10
From these values, the energy change for this OeT process,
nced signal-to-background
ΔG-5PeT, is calculated to be −0.37 eV, indicating that electron
cer cells without the typical -3.0x10
transfer from the excited dye to the electron-poor quinone is
removal from the environthermodynamically
favorable. The quinone was attached to the
-5
probe provides for real-time, -4.0x10
naphthalimide
a
1.5
1.0 via an
0.5N-methylethanolamine
-1.0 -1.5 -2.0linker
-2.5 through
-3.0
man tumor cell analysis and
carbamate to the amine of the naphthalimide ring. This linker
E(V)
ntent.
imparts three crucial properties on Q 3NI: the linker is
suﬃciently short to allow for a high probability of electron
transfer,
the electron-withdrawing
a favorable
N
Figure 3.3
Cyclic
voltammetry
of Q3Nap andcarbamate
Q3PA at ayields
3-mm
diameter glassy carbon
ΔG
,
and
the
presence
of
the
tertiary
amide
PeT
working
electrode using 0.1 M tetrabutylammonium23,25
perchlorate in provides
acetonitrile; T = 25 °C; Scan
s Controlled by
Photo−1
enhanced
environmental
stability.
As a result, the
rate
was
0.1
V
s
.
) Quenching. We designed
ﬂuorescence of Q 3NI in pH 7.4, 0.1 M PBS is eﬀectively
ﬂuorescence signal of its
quenched in comparison to that of the free NI reporter, as
hed via oxidativedonor
electronNap andnoted
the potential
propionic
acceptor of Q3Nap were
by their Espectra
in quinone
Figure 1B,C
and acid
respective
A of the
attached quinone propionic
ﬂuorescence quantum yields (Φ) of 0.007 and 0.23 obtained
1.08 V and −1.05 V respectively.
From Figure 3.4 the energy of the first excited
d that it would bedetermined
possible to to beusing
quinine sulfate as standard.26 The quantum yield for NI is
of reporter quenching by
superior
or comparable to that of other dyes applied to 2cancer
singlet
00) of the Nap reporter, was found to be 3.05 eV; e /εd which is the Coulombic
d optical properties
of state
the (ΔGdetection
and localization, such as Φ = 0.0028 for indocyanine
13,27 these values, the energy change for
phthalimide reporter
NI, due energy
interaction
of
the
ion
pair,
to be
0.06 eV.
green and Φ
= known
0.21 for
Cy5.5
dyes.From
The 33-fold
ﬂuorescence enhancement for NI versus Q 3NI and very large
the OeT quenching, ΔGPeT, is calculated to be −0.98 eV, indicating that electron transfer from the
Stokes shift of 116 nm (λmax, abs = 374 nm, λmax, em = 490 nm)
well electron-poor
for use of Q 3NI
as a multifunctional
turn-on
probe
excited Nap dyebode
to the
quinone
propionic acid
is thermodynamically
feasible.
for sensing and imaging applications that utilize reductive
Similarly, a significantly
favorable
ΔGPeT ofremoval
−1.44 eV
computed
for the reductive quenching
stimuli capable
of initiating
of was
the reduced
quinone
28−31
group.
Fluorescence Dequenching of Q3NI is Achieved by
Reduction-Initiated Removal of
86Quinone. We then wished
to determine if it is possible to produce the NI reporter from
the Q 3NI probe by the expected cyclizative cleavage reaction of
the hydroquinone via the gem-dialkyl eﬀect32 that occurs
28

process (ReT) of the Nap reporter by the reduced quinone (hydroquinone), pointing to its

Absorbance of Q3Nap in ACN

1.0

800

0.8

600

0.6
400
0.4
200

0.2
0.0
300

350

400

450

500

Q3Nap in ACN (RFU, λex = 360 nm)

thermodynamic favorability.

0
600

550

Wavelength (nm)

Figure 3.4

Q3Nap absorption (black) and emission (Red) in Acetonitrile solution; T = 25 °C.

This latter ReT process of quenching the reporter fluorescence by electron rich species
(e.g. hydroquinone, Figure 3.5) is a common feature with naphthalimide dye.
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Schematic representation of the novel PeT quenching of Q3Nap, proposed
quenching mechanism for Q3Nap, and subsequent self-immolation to release the fluorescent Nap
reporter.
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3.3.3

Quantum yield
Fluorescence quantum yield measurements were carried out using dilute dye solutions

where absorbance was between 0.02-0.08. An amount of 3 mL from these solutions were
transferred to 1-cm × 1-cm quartz cuvettes and subjected to fluorescence measurements.

ΦF(X) = (As/Ax) (Fx/Fs) (nx/ns)2 ΦF(S)

Equation 2

The quantum yields were calculated relative to two different standard solutions, 1)
coumarin in EtOH (Φ = 0.54)26 for Nap, and 2) quinine sulfate in 1 N H2SO4 (Φ = 0.51)26 for
Q3Nap using the Equation 2, where Φ F is the fluorescence quantum yield, A is the absorbance at
the excitation wavelength, F is the area under the corrected emission curve and n is the refractive
index of the solvents used. Subscripts S and X refer to the standard and the unknown,
respectively.27 In this equation, absorbance A accounts for the number of absorbed photons and
area F accounts for the number of emitted photons. Quantum yields for Φ(Q3Nap) and

Φ(Nap)were obtained in aqueous media under physiological conditions (0.1 M phosphate buffer,
pH =7.4) and were calculated at 0.002 and 0.19 respectively. This large difference (95-fold
fluorescence enhancement) in quantum yields is due to photo induced electron transfer (PeT)
quenching of the naphthalimide reporter by the Q3PA trigger group. To further evaluate this
outcome, voltammetric measurements were carried out and are described in the next section.
3.3.4

Reduction-initiated, self-immolative, turn-on response of Q3Nap
The striking difference in both the absorption (λreport
is red shifted roughly 50 nm in
abs

comparison to λprobe
, 432 nm vs 380 nm), and the emission (λreport
vs λprobe
, 532 nm vs 480 nm),
abs
emis
emis
prompted the possibility of Q3Nap’s use as a ratiometric probe in these studies. However, the
large difference in quantum yields of the Q3Nap probe and the Nap reporter did not bode well for
the ratiometric concept. To test this, Q3Nap was excited at different wavelengths (Figure 3.6): A)
at the maximum absorbance of Q3Nap, λex =380 nm; B) at the intersection of the two
absorbances of Q3Nap and Nap λex =400 nm; and C) at the maximum absorbance of the Nap
reporter λex =432 nm. In each instance the probe was subjected to dithionite-initiated reduction
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Figure 3.6
Fluorescence turn-on response of 2 µM Q3Nap at with different excitation, (A) λex
= 380 nm, (B) λex = 400 nm, and (C) λex = 432 nm in pH 7.40, 0.1 M phosphate buffer with 16
µM sodium dithionite; T = 25 °C.
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possible imaging applications.
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The Nap reporter is quickly turned on (t1/2∼6 min) under physiologically relevant
conditions, pointing to the rapid self- immolative cleavage of the N-methyl-p-aminobenzyl
alcohol and loss of CO2 to yield the Nap reporter. This occurs because of the electron-rich
character of the N-methyl-p-aminobenzyl alcohol versus that of the more typically encountered
p-aminobenzyl alcohol linker. The release of the Nap reporter after the initial reduction by
dithionite was evident by the appearance of an absorption band centered at 432 nm (Figure 3.8),
which matched exactly with the free Nap absorption band in PBS.
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Figure 3.8
Demonstration of the changes in absorption spectra of 2 µM Q3Nap black, before
and red, after the addition of 16 µM sodium dithionite in pH 7.40, 0.1 M phosphate buffer; T =
25 °C.
This conversion was also confirmed by mass spectrometric analysis of Q3Nap solutions
treated with dithionite (Figure 3.9). The result clearly show the three products generated; Nap
reporter, Q3lactone, and the N-methyl-p-aminobenzyl alcohol.
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(A)

(B)

•

✶

Figure 3.9
Positive-ion electrospray mass spectra of Q3Nap (A–before reduction) and after
reduction (B–with dithionite) to yield Nap, N-methyl-p-aminobenzyl alcohol linker, and the
lactone. Q3Nap [M+H]+ signal is observed at m/z 664.3012 (expected m/z 664.3018 [M+H]+, 0.9
ppm error). ✶ Nap [M+H]+ signals observed at m/z 269.1285 and (expected m/z 269.1285
[M+H]+, 0.0 ppm error). • Lactone [M+H]+ signals observed at m/z 235.1328 (expected m/z
235.1329 [M+H]+, 0.4 ppm error). Linker [M+H]+ signals observed at m/z 138.0913 (expected
m/z 138.0914 [M+H]+, 0.7 ppm error).
3.3.5

Q3Nap activation by hNQO1 enzyme
The fast turn-on response observed in the dithionite–initiated reduction studies, suggests

that the use of Q3Nap should allow for the detection of NQO1 enzyme activity. To test whether
human NQO1 can initiate the decloaking of Q3Nap to reveal the free Nap reporter upon
activation of the quinone trigger group, the formation of the fluorescent product, with different
concentrations of probe, was monitored over time in the presence of a constant amount of
enzyme. For quantitative evaluation of Q3 activation by human NQO1, I monitored the
fluorescence intensity increase of solutions of Q3Nap (2−60 × 10−6 M) with a fixed amount of
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human NQO1 (4 × 10−5 g) and its cofactor NADH (1 × 10−5 M). The fluorescence intensity was
converted to concentration of the free Nap reporter, using a calibration curve. Control
experiments with NADH alone did not yield significant changes in fluorescence, a result in
accordance with that previously shown for the Q3PA trigger group. From these experiments, the
initial rate of product formation, V (µmol min−1mg.hNQO1−1), was calculated and plotted as a
function of Q3Nap concentration (Figure 3.10).
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Figure 3.10 Kinetics of human NQO1 (4 ×10−5 g) with Q3Nap (2−60 ×10−6 M) in pH 7.4, 0.1
M phosphate buffer. Values (n = 3) are the average ±1 sample standard deviation. The curve is
the best fit to the average data; T = 25 °C.
Apparent kinetic parameters were then obtained by fitting the data in Figure 3.10 to the
Michaelis-Menten equation,29 which provides the Michaelis constant (Km) = 10.4 ± 1.0 µM,
maximum velocity (Vmax) = 0.00225 ± 0.00008 µmol min−1mg.hNQO1−1, catalytic constant (kcat)
= 0.068 ± 0.002 min−1, and catalytic efficiency (kcat/Km) = 6.52 ± 0.67 ×103 M−1min−1. In
addition, the Q3PA trigger group is stable to reduction/addition reactions in the presence of
glutathione and ascorbate as well as dithiothreitol. Also, there is no apparent inhibition of
hNQO1 activity with the [Q3Nap] values studied. The results indicate that an efficient reporter
release of the reporter occurs with the interaction between Q3Nap and human NQO1 under
physiological conditions. However Q3Nap activation by hNQO1 was slow compared to Q3NI,6 a
previously reported probe in our group. I postulate this is due to the p-aminobenzyl alcohol
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linker locking the geometry into one orientation, such that the flexibility the Q3Nap is hindered
to access the hNQO1 catalytic site. Much faster enzyme kinetics was observed for a different
probe with a flexible linker, which will be discussed in chapter 4.
3.3.6

Differentiating and visualizing cancer cells that overexpress hNQO1
I next sought to apply Q3Nap for fluorescence imaging of various cancer cell lines.

Specifically, the probes’ ability to differentiate cancer cell lines based on hNQO1 content
(positive vs negative), by exposing live hNQO1-positive and hNQO1-negative cells to Q3Nap
under typical culture conditions (37 °C/CO2 atmosphere) as depicted in Figure 3.11.
DIC
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HT29
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Q3Nap

Figure 3.11 Microscopy images of hNQO1-positive HT29 colon (A, B, C) and hNQO1negative H596 lung (D, E, F) cancer cells after incubation at 37 °C with 2 × 10−5 M Q3Nap.
Confocal images in A, B, D, and E; differential interference contrast in C and F. DRAQ5 nuclear
stain was used for B and E. Scale bar = 20 μm.
Confocal fluorescence microscopy images of fixed hNQO1-positive colorectal cancer
cells (HT29) incubated with Q3Nap indicated significant Q3Nap uptake and activation, resulting
in intense intracellular Nap production. However, hNQO1-negative nonsmall cell lung cancer
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cells (H596) treated with Q3Nap revealed minimal production of Nap reporter (Figure 3.11).
These results suggest that Q3Nap is stable in the intracellular environment of NQO1-negative
cell line, pointing to the fact that the production of the Nap reporter is possible only in the
presence of hNQO1. In addition similar behavior was observed in another amide-linked
napthalimide reporter, Q3NI. Wide-field fluorescence micrographs yielded similar results. Upon
statistical evaluation of the fluorescence intensities in confocal images of hNQO1-positive (35
samples) and hNQO1-negative (29 samples) cells like those in Figure 3.11, a value of 11 was
found for the positive-to-negative ratio (Figure 3.12). Similarly, for wide-field fluorescence
images (33 positive samples/20 negative samples), a PNR of 510 was observed. Thus, the PNR
value of ∼500 obtained with Q3Nap/Nap is unprecedented in the context of our previous work
with identical cell lines, and this value can be improved in wide-field measurements by the use
of a filter set (BCECF) that more completely encompasses the emission profile of Nap. It is
important to note that this significantly decreased background (negative) signal is achieved via
several factors, 1) the unique PeT quenching gives rise to an exceedingly large difference in
fluorescence efficiency between the quenched probe and the free Nap reporter (95-fold increase);
2) the shift of wavelength to the red by 100 nm in both the energies over which Q3Nap/Nap
reporter is excited/emits light, and 3) the corresponding lower molar absorptivity of Q3Nap vs
Nap reporter at the excitation maximum of Nap reporter, in Q3Nap’s design.
3.3.7

Q3Nap selectivity towards NQO1 over its isoenzyme NQO2
Human NAD(P)H: quinone oxidoreductase 2 (NQO2, EC 1.10.99.2)30 is a cytosolic

homodimeric flavoprotein with one FAD prosthetic group per monomer. Like NQO1, NQO2
also catalyzes a two-electron reductive metabolism of quinones and its derivatives, and has a
49% identity between their amino acid sequences.31 They both utilizes pyridine nucleotide as
cofactors; however, NQO2 differs from NQO1 in that it prefers a smaller dihydronicotinamide
riboside (NRH) as the co-substrate, instead of NAD(P)H. In comparison to NQO1, NQO2 is
usually expressed at very low levels in human solid tumors, but is expressed at higher levels in
red blood cells and in leukemias.32 To study the selectivity of Q3Nap probe towards NQO1,
NQO2 enzyme assay was conducted as described 3.2.4. The Co-substrate 14 was synthesized
according to a previously reported method, which is known to have greater stability and activity
over NRH.
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Figure 3.12 Integrated intensities for positive and negative NQO1 cell images obtained with
confocal and widefield microscopy, with average positive and negative values in yellow and the
positive-to-negative ratio (PNR) in the red boxes.
96

As shown in Figure 3.13, a fluorescence enhancement, by Q3Nap activation and
subsequent Nap reporter production, was higher in NQO1 enzyme assay, while NQO2 showed
no Nap reporter production over a period of one hour.
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Figure 3.13 Time-dependent fluorescence spectra (λex = 432 nm, λem = 540 nm) of Q3Nap (5 ×
10−5 M) upon exposure to 40 µg human NQO2 (A) in the presence of 100 µM reduced
nicotinamide co-factor in pH 7.4, 0.1 M PBS/0.1 M KCl/0.007% BSA buffer showing the lack of
reduction-induced production of Nap, versus Q3Nap activation in the presence of 4 × 10−5 g
hNQO1 (B) under similar conditions.
3.4

Conclusions
I have presented the synthesis, spectroscopic properties and kinetic evaluation of a novel

self-immolative quenched turn-on fluorescent probe, which features a unique photoinduced
electron-transfer quenching mechanism, that can be modulated by a reduction initiated removal
of a cancer-associated-enzyme substrate. Specifically, reduction of the trimethyl quinone
propionic acid substrate by NADP(H): quinone oxidoreductase triggers the removal of the selfimmolative spacer, which spontaneously falls apart releasing the naphthalimide fluorescent
reporter possessing a highly intense emission and dramatic change in Stokes shift. I have clearly
demonstrated that the turning-on of Q3Nap, under physiological solution conditions has a
sensitive response to human NQO1. This is achieved in a highly selective fashion from dramatic
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fluorescence enhancement of the production of red-shifted Nap reporter, generated only upon
hNQO1 action on the trigger group of the Q3Nap probe. This was evident by the studies
conducted with hNQO1-positive HT29 and hNQO1-negative H446 cancer cell lines, resulting in
Q3Nap activation with unprecedented PNR values.
The self-immolative linker is important for Q3Nap’s mode of action and for its unique
spectroscopic properties, mainly providing, 1) a shiftable wavelength, 2) environmental stability,
3) faster signal relay kinetics and efficient quenching. In addition, the release studies conducted
with sodium dithionite showed faster Nap production under physiological conditions, but the
hNQO1 activation of Q3Nap was rather slow, with fairly high binding constants and low
catalytic turnover numbers. This may be due to the fact that, the rigid self-immolative linker
locking the geometry of Q3Nap into one position, resulting in a loss of its flexibility when
binding to the catalytic site of the hNQO1 enzyme. However, with regard to longer-term
impacts, these types of enzyme-activatable probes, will serve as an important step towards a new
generation of compounds attractive for use as “intelligent” imaging agents in fluorescenceassisted studies of cancerous tissues providing real-time information on tumor cell
microenvironment, and efficacy studies of personalized chemotherapy.10,33
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CHAPTER 4
DESIGN, SYNTHESIS, AND EVALUATION OF A PROFLUOROGENIC NIR TURNON SUBSTRATE-PROBE FOR DETECTION AND IMAGING OF CANCER CELLS
4.1

Introduction
Fluorescence imaging is expected to have a significant impact on future personalized

oncology, owing to its high temporal and spatial resolution. The design of fluorescence imaging
probes that can detect chemical or biological analytes with high selectivity and sensitivity is
especially desired for in vivo imaging. To date, most of the reported probes have been tested for
in vitro use, and they possess absorption and emission energies in the ultraviolet/visible range,
which makes them less useful in sensing and imaging targets of interests in living animals. This
is mainly due to the high absorbance of biomolecules (e.g. water and hemoglobin), scattering
events, auto-fluorescence of the tissue environment matrix, and limited tissue penetration depths,
all of which lead to low signal-to-background (SBR) ratios.1-2
Designing versatile fluorophores that emit in the near-infrared (NIR) region (650–900
nm) will help mitigate some of these issues.3 NIR fluorescence imaging is advantageous for a
wide variety of in vivo applications, mainly because of the minimal background interference and
improved tissue depth penetration.4-5 On the other hand, activatable/turn-on probes6 provide a
higher SBR ratio than the more conventional “always-on” probes.2 A high SBR is desirable for
cancer imaging, as it helps to identify diseased tissues from healthy ones, providing real-time
information on tumor cell microenvironment. It is advantageous to design imaging probes that
have a built-in mechanism for the controlled switching on of their optical properties in response
to a user designated reaction or an enzyme-triggered event in cancer cells,7 the latter which is the
focus of this work. Currently, Förster resonance energy transfer (FRET), photo-induced electron
transfer (PeT), and internal charge transfer (ICT) approaches provide a gateway to develop turnon fluorescent probes.8-10
To date, only a small number of endogenous, intracellular, distinct cancer-linked
enzymes have been targeted by a handful of small-molecule, turn-on probes that can be used to
selectively image cells with improved SBRs.11-12 In this respect, NAD(P)H: quinone
oxidoreductase-1 (NQO1, DT-diaphorase, EC 1.6.99.2) received great interest as a target in both
cancer-related prodrug therapies and molecular imaging research. In the previous chapter I have
shown the synthesis of a unique PeT-quenched probe, Q3Nap,13 and demonstrated its ability to
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allow imaging of NQO1-positive cancer cell lines, with unprecedented SBRs, but its emission
lies in the range of 500–550 nm, limiting its applicability for in vivo deep tissue imaging.
Cyanines, due to their spectroscopic characteristics, have received immense attention in
the construction of fluorescent labels for NIR imaging.14-15 In general, the excitation and
emission wavelengths of cyanine dyes are well separated from the shorter wavelength autofluorescence generated from chromophores and macromolecules present in analyte or tissue
samples. For decades, indocyanine green (ICG) has been used in the clinic as a contrast agent,
and it is the only FDA-approved imaging agent in humans that emits in the λ > 650 nm energy
region.4,16-17 However, ICG is an always-on reporter, and its absorption and/or fluorescence
properties cannot be altered upon specific reaction with biomolecules. This limits the potential
utility of ICG in development of activatable probes for bimolecular imaging applications.
However, a novel strategy has recently been reported based on control over the electron
delocalization through the π-conjugated backbone of a cyanine based fluorophore by trigger
group cleavage (Figure 4.1).18-19 This trigger group removal and subsequent deprotonation result
in the formation of the phenolate active donor, which then orients itself to donate the π-electron
pair to either one of the acceptor groups, restoring the ICT character.
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Schematic depiction of the activation of cyanine-based sensors.18
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Donor

Several dyes were synthesized with different acceptor groups and charge states with the
intention of developing an enzyme-activatable NIR probe (Figure 4.2). Due to its longer NIR
emission (Figure 4.3), and hydrophilic and zwitterionic charged nature, dye c (Cy) was selected
in the development of a first generation, NQO1-activatable, near-infrared probe.
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Figure 4.2
Series of anionic, cationic, and zwitterionic donor-acceptor dyes with indolium
and picolinium acceptor groups.
The designed tripartite probe Q3Cy, consists of a trimethyl-locked quinone propionic acid
trigger group linked to a fluorescently cloaked heptamethine cyanine fluorophore (Cy) by an
N,N-dimethylethylenediamine linker (Scheme 4.1). Q3Cy was designed so as to yield minimized
NIR fluorescence of the Cy reporter by masking the phenolate moiety (donor), resulting in the
disruption of the π-conjugated backbone between the two quaternary indolium groups (acceptor).
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reporter.

Mechanism of NQO1-enzyme-induced decloaking of Q3Cy to reveal the Cy

The enzymatically-triggered reductive removal of the quinone head group, followed by
subsequent cyclization of the linker, is anticipated to result in unmasking of the phenolate
functionality in the Cy reporter. This should then lead to restoration of the extended
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π-conjugation between the donor and the acceptor groups so as to offer turn-on NIR
fluorescence. Furthermore, decloaking of the Cy reporter gives rise to a unique color change,
making Q3Cy a colorimetric “naked-eye-probe” for NQO1.
4.2

Experimental

4.2.1

Synthetic material and methods
All chemicals were purchased from Sigma-Aldrich or Fisher Scientific and used as

received. Column chromatography was performed on 50-g SNAP silica columns using a
Flashmaster Personal from Biotage. Thin layer chromatography was performed on aluminumbacked 60 F254 silica plates from EMD Chemicals Incorporated. 1H and 13C NMR spectra were
collected in CDCl3, DMSO-d6, or methanol-d4 at room temperature on a Bruker AV-400. All
chemical shifts are reported in the standard δ notation of parts per million using tetramethylsilane
as an internal reference. Absorption bands in NMR spectra are listed as singlet (s), doublet (d),
triplet (t), multiplet (m), or two triplets (2t), and coupling constants (J) are reported in hertz (Hz).
Mass spectral analyses were carried out using an Agilent 6210 ESI-TOF mass spectrometer.
4.2.2

Synthesis of acceptor groups

2,3,3-Trimethyl-1-(3-sulfonatepropyl)-3H-indolium (15):20
O
S O
O
N

1,2-dichlorobenzene

N
15

O3S

To 2,3,3-trimethylindolenine (500 mg, 3.14 mmol) was added a solution of 1,3-propane sultone
(422 mg, 3.45 mmol) in 1,2-dichlorobenzene (3 mL). The reaction mixture was stirred at 120 °C
overnight. The purple precipitate (804 mg, 91%) was collected by filtration, washed with cold
diethyl ether, and dried in vacuo. 1H NMR (500 MHz, deuterium oxide, d2) δ 7.84 – 7.76 (m,
1H), 7.75 – 7.66 (m, 1H), 7.64 – 7.54 (m, 2H), 4.70 – 4.52 (m, 2H), 3.08 (t, J = 7.1 Hz, 2H), 2.45
– 2.28 (m, 2H), 1.53 (s, 6H). ESI-MS: for C14H19NO3S: expected m/z = 282.1159 [M+H]+; found
m/z = 282.1158 [M+H]+; 0.35 ppm error.
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Compound (16):
O
S O
O
N

N

1,2-dichlorobenzene

16

O3S

A mixture of 4-picoline (1.36 mL, 14.0 mmol), 1,3-propanesultone (2.60 g, 21.3 mmol) and 1,2dichlorobenzene (7 mL) was heated at reflux overnight. The precipitate formed was filtered, and
washed with acetone, and then recrystallized from EtOH to give compound 16 (2.40 g, 80%) as a
white solid/powder. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 8.80 (d, J = 6.6 Hz, 2H), 7.86
(d, J = 6.3 Hz, 2H), 4.54 (t, J = 7.0 Hz, 2H), 2.49 (s, 3H), 2.29 (t, J = 7.1 Hz, 2H), 2.09 (t, J = 7.0
Hz, 2H).

13

C NMR (101 MHz, chloroform-d) δ 159.31, 144.28, 128.80, 59.24, 47.39, 27.60,

21.84. ESI-MS: for C9H13NO3S: expected m/z = 216.0689 [M+H]+; found m/z = 216.0692
[M+H]+; 1.39 ppm error.
1,2,3,3-tetramethyl-3H-indolium iodide (17):

I
N

N

Toluene

I

17

2,3,3-trimethyl-3H-indolenine (2.0 g, 12.5 mmol) and iodoethane (3.3 g, 20.6 mmol) in 60 mL
toluene were stirred overnight at 100 °C (under N2). After of which, the mixture was filtered, and
the precipitate was washed with diethyl ether and then dried to afford a pink solid (3.12 g, 79.5
%). 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 8.03 – 7.93 (m, 1H), 7.90 – 7.82 (m, 1H), 7.68
– 7.58 (m, 2H), 4.51 (q, J = 7.3 Hz, 2H), 2.85 (s, 3H), 1.54 (s, 6H), 1.45 (t, J = 7.3 Hz, 3H). ESIMS: for C13H18N+: expected m/z = 188.1434 [M]+; found m/z = 188.1450 [M]+; 8.5 ppm error.
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Potassium 2,3,3-Trimethyl-3H-indole-5-sulfonate (19):
SO3H

O3S NH4

KO3S
KOH

O
AcOH
H2N

iPrOH,
MeOH

N

NH

N

18

19

A mixture of 4-hydrazinobenzene sulfonic acid (60 g, 319 mmol), and 3-methyl-2-butanone (45
mL, 418 mmol) in glacial acetic acid (300 mL) was heated at 118 oC under a nitrogen
atmosphere overnight. The crude product was filtered and collected as a pink solid after
precipitation in ethyl acetate to obtain 18 (65 g, 80%).
Compound 18 (65 g, 254 mmol) was dissolved in methanol (500 mL). A potassium
hydroxide solution prepared from potassium hydroxide (17 g, 300 mmol) and 2-propanol (200
mL) was added into solution of 18 using a dropping funnel for 1 h in a gentle heating condition.
The crude mixture was filtered, washed with 2-propanol and ethyl acetate, and 19 was collected
as a brown solid (55 g, 78%). 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 7.64 (s, 1H), 7.56 (d,
J = 7.8, 2.0 Hz, 1H), 7.34 (d, J = 7.9, 1.9 Hz, 1H), 2.21 (d, J = 1.9 Hz, 3H), 1.25 (d, J = 2.0 Hz,
6H). ESI-MS: for C11H12KNO3S: expected m/z = 278.0248 [M+H]+; found m/z = 278.0261
[M+H]+; 4.67 ppm error.
4.2.3

Synthesis of anionic, cationic, and zwitterionic donor-acceptor dyes

Dye (a):
N
N
N

O

N
I
O3S

HO
EtOH, Piperidine

O

HO

15

HO

EtOH, Piperidine

20

Dye a

O

N
O3S

4-Hydroxyisophtalaldehyde (0.20 mmol), piperidine (0.21 mmol), and picolinium iodide (0.21
mmol) were dissolved in EtOH. The reaction mixture was stirred for 30 min at 80 oC under an Ar
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atmosphere. After completion, the reaction mixture was concentrated by evaporation under
reduced pressure. The crude product was further used without purification. ESI-MS: for
C15H14NO2+: expected m/z = 240.1019 [M]+; found m/z = 240.1019 [M]+; 0.00 ppm error.
A mixture of crude compound 20 (0.20 mmol), piperidine (0.21 mmol), and indolium
derivative 15 (0.21 mmol) was dissolved in EtOH 1.5 mL. The reaction mixture was stirred for 1
h at 80 oC under an Ar atmosphere. After completion, the reaction mixture was concentrated by
evaporation under reduced pressure. The crude product was diluted with 1:1:0.1 H2O: ACN:
AcOH, and purified by preparative RP-HPLC (grad. 10%-90 ACN in water, 20 min) to give Dye
a (67%) as a red solid. 1H NMR (500 MHz, methanol-d4) δ 8.98 (d, J = 2.2 Hz, 1H), 8.87 (d, J =
16.4 Hz, 1H), 8.67 (d, J = 6.3 Hz, 2H), 8.33 (d, J = 6.7 Hz, 2H), 8.20 – 8.13 (m, 1H), 7.94 (d, J =
8.9 Hz, 2H), 7.84 – 7.79 (m, 1H), 7.75 (d, J = 8.6, 2.1 Hz, 1H), 7.72 – 7.64 (m, 3H), 7.07 (d, J =
8.6 Hz, 1H), 5.05 – 4.97 (m, 2H), 4.32 (s, 3H), 3.18 – 3.11 (m, 2H), 2.50 (tt, J = 8.8, 5.3 Hz, 2H),
1.89 (s, 6H). ESI-MS: for C29H31N2O4S+: expected m/z = 503.1999 [M]+; found m/z = 503.1999
[M]+; 0.00 ppm error.
Dye (b):
N
N

O
OH

EtOOC

TFA, HMTA

I

OH
OH

EtOH, Piperidine

EtOOC

EtOOC

O
21

Dye b

N

A mixture of commercially available ethyl-4-hydroxy benzoate (6 mmol) and HMTA (24.8
mmol) was dissolved in 7 mL of TFA. The reaction was refluxed (95 oC) overnight using a Dean
Stark system, and cooled to room temperature. 40 mL of water were added and the reaction was
heated to 80 oC for 2 h. After cooling to room temperature, the product precipitated as a yellow
solid. 1H NMR (400 MHz, chloroform-d) δ 12.00 (s, 1H), 10.23 (s, 2H), 8.60 (d, J = 1.7 Hz, 2H),
4.37 (q, J = 7.1 Hz, 2H), 1.57 – 1.04 (m, 3H). ESI-MS: for C11H10O5: expected m/z = 221.0455
[M-H]; found m/z = 221.0456 [M-H]; 0.45 ppm error.
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A mixture of dialdehyde 21 (0.06 mmol), piperidine (0.12 mmol), and picolinium iodide (0.12
mmol) was dissolved in EtOH. The reaction mixture stirred for 6 h at 80oC under an Ar
atmosphere. After completion, the reaction mixture was concentrated by evaporation under
reduced pressure. The crude product was diluted with 1:1:0.1 H2O: ACN: AcOH, and purified by
preparative RP-HPLC (grad. 10%-90% ACN in water, 20 min) to give Dye b (90%) as a yellow
solid. 1H NMR (400 MHz, methanol-d4) δ 8.73 (d, J = 6.6 Hz, 4H), 8.43 (s, 2H), 8.18 (d, J = 6.5
Hz, 4H), 7.53 (d, J = 16.2 Hz, 2H), 4.41 (q, J = 7.1 Hz, 2H), 4.32 (s, 6H), 1.42 (t, J = 7.1 Hz,
3H). ESI-MS: for C25H26N2O32+: expected m/z = 210.0967 [M]2+; found m/z = 201.0967 [M]2+;
0.00 ppm error.
Cy (Dye c):
O3S

N

N
O
O3S

HO

15

HO

NaOAc, Ac2O

O

N
O3S
Cy

A mixture of 4-hydroxyisopthaldehyde (20 mg, 0.13 mmol), NaOAc (33.9 mg, 0.41 mmol), and
compound 15 (79 mg, 0.27 mmol) was dissolved in 1 mL Ac2O. The reaction mixture was stirred
for 30 minutes at 80 oC under an Ar atmosphere. After completion, the reaction mixture was
concentrated by evaporation under reduced pressure. The acetate derivative was dissolved in 4
mL MeOH. K2CO3 (cattalytic amount) was added to the suspension, and the reaction mixture
was stirred at room temperature for 60 min with monitoring by RP-TLC (35% ACN in water, Rf
= 0.44). After completion, the reaction mixture was diluted with 4 mL H2O, 800 µL AcOH, and
then chromatographed (C-18 silica, 10%-90% AcCN in H2O) to provide Cy (44 mg, 51%) as a
red solid. 1H NMR (400 MHz, methanol-d4) δ 9.13 (s, 1H), 8.78 (d, J = 16.4 Hz, 1H), 8.56 (d, J
= 16.0 Hz, 1H), 8.29 (d, J = 8.9 Hz, 1H), 8.18 (d, J = 16.3 Hz, 1H), 8.00 – 7.86 (m, 3H), 7.84 –
7.73 (m, 2H), 7.65 (dd, J = 12.7, 10.1, 6.7 Hz, 4H), 7.16 (d, J = 8.9 Hz, 1H), 4.99 (d, J = 21.1,
8.1 Hz, 4H), 3.11 (dt, J = 12.3, 6.3 Hz, 4H), 2.46 (d, J = 14.2, 7.4, 6.6 Hz, 4H), 1.91 (d, J = 15.1
Hz, 12H). 13C NMR (101 MHz, methanol-d4) δ 182.50, 164.02, 154.57, 148.10, 143.28, 140.79,
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137.67, 132.96, 129.61, 129.31, 129.27, 129.14, 127.12, 122.74, 122.66, 122.56, 117.46, 114.73,
114.42, 112.44, 110.44, 70.06, 52.44, 45.46, 45.10, 29.35, 25.82, 25.61, 24.07, 23.99. ESI-MS:
for C36H40N2O7S2: expected m/z = 677.2350 [M+H]+; found m/z = 677.2357 [M+H]+; 1.03 ppm
error.
O3S

Dye (d):

N

N

O
OH
EtOOC
O

O3S

15

OH

NaOAc, Ac2O

21

EtOOC
Dye d

N

SO3

The reaction procedure was the same as the Cy synthesis, but with dialdeyde 21 and sulfonated
indole 15. ESI-MS: for C29H32N2O9S2: expected m/z = 617.1622 [M+H]+; found m/z = 617.1647
[M+H]+; 4.05 ppm error, and expected m/z = 309.0848 [M+2H]2+; found m/z = 309.0859
[M+2H]2+; 3.55 ppm error.
SO3

Dye (e):
OH

N

N
OH

OH O
O3S

TFA, HMTA

15

NaOAc, Ac2O
22

O

N
O3S

Dye e

1-Naphthol (1.0 g, 6.9 mmol) was dissolved in 10 mL of TFA. Hexamethylenetetramine (1.94 g,
13.8 mmol) was added in and the reaction mixture was heated to reflux for 1 h. The reaction was
allowed to cool to room temperature and 10 mL of 33% H2SO4 was added. The reaction mixture
was heated to reflux and stirred for an additional 1 h, and then it was poured into water. The
crude product was extracted twice with EtOAc and then washed with brine. The organic layer
was dried over MgSO4, and filtered, and then the solvent was removed under reduced pressure.
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The crude product was purified by column chromatography on silica gel (EtOAc/ Hex 3:7) to
afford compound 22 (995 mg, 71%) as a yellow solid.
Dye e was synthesized following a similar procedure for the synthesis of Dye c, but using
32. 1H NMR (400 MHz, methanol-d4) δ 9.19 (s, 1H), 8.85 (m, 2H), 8.46 (d, 1H), 8.06 (m, 2H),
7.76 (m, 2H), 7.64 (m, 3H), 7.48 (m, 4H), 7.21 (m, 1H), 7.01 (m, 1H), 4.76 (s, 4H), 3.15 (s, 4H),
2.43 (s, 4H), 1.89 (s, 12H). ESI-MS: for C40H42N2O7S2: expected m/z = 727.2506 [M+H]+; found
m/z = 727.2498

[M+H]+ and expected m/z = 364.1290 [M+2H]2+; found m/z = 364.1293

[M+2H]2+; 0.82 ppm error.
4.2.4

Synthesis of the Q3Cy probe (Scheme 4.2).
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Scheme 4.2

O3S

Synthesis of Q3Cy.

Mono-Boc-N-N-dimethyl-ehtylendiamine (23):
N,N-Dimethyl-ethylendiamine (10 g, 113 mmol) was dissolved in DCM (120 mL), and the
solution was cooled by ice water. Di-tert-butylcarbonate (8.3 g, 38 mmol) in DCM (60 mL) was
added dropwise at 0 oC. After the addition ended the reaction was allowed to warm to room
temperature and was stirred overnight. The solvent was then removed under reduced pressure
and the crude mixture was dissolved in EtOAc and was washed with brine. The organic solution
was dried over magnesium sulfate and filtered. Solvent was removed under reduced pressure, to
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provide compound 23 as a pale yellowish oil (6.5 g, 34.5 mmol) with 91% yield. 1H NMR (400
MHz, chloroform-d) δ 3.30 (t, J = 6.9 Hz, 2H), 2.84 (s, 3H), 2.69 (t, J = 6.6 Hz, 2H), 2.41 (s,
3H), 1.42 (s, 9H), 1.39 – 1.31 (m, 1H). ESI-MS: for C9H20N2O2: expected m/z = 189.1598
[M+H]+; found m/z = 189.1590 [M+H]+; 4.23 ppm error.
Q3PA-diamine-BOC (24):
Compound 23 (2.0 g, 10.6 mmol) was dissolved in a solution of Et3N (5 mL) in 10 mL of DMF.
In a separate flask, EDCI (4.134 g, 21.2 mmol) and HOBT (2.862 g, 21.2 mmol) were introduced
to a solution of Q3PA acid (2.65 g, 10.6 mmol) in 15 mL of DMF and subsequently stirred for
1 h. Resulting mixture was then added dropwise to the mono BOC-protected amine solution at
room temperature and then stirred overnight under N2. The solution was diluted with ethyl
acetate washed with water, and then dried with MgSO4, with subsequent solvent removal
by evaporation under reduced pressure. The crude material was purified by flash
chromatography using a gradient Hex:EtOAc, 7:1 to Hex:EtOAc, 3:2 (Rf =0.44) to afford the
desired compound 24 as an oil (2.88 g, 6.8 mmol, 65%). 1H NMR (400 MHz, chloroform-d) δ
3.40–3.04 (m, 4H), 2.91–2.61 (m, 8H), 1.95 (d, J = 3.1 Hz, 3H), 1.75 (d, J = 9.8 Hz, 6H), 1.41–
1.14 (m, 15H). ESI-MS: for C23H36N2O5: expected m/z = 421.2697 [M+H]+; found m/z =
421.2704 [M+H]+; 1.66 ppm error.
Q3PA-diamine-TFA salt (25):
A solution of 24 (2.8, 6.8 mmol) and trifluoroacetic acid (10 mL) in 20 mL of CH2Cl2 was stirred
for 2 h. The solution was evaporated under reduced pressure. The crude material was used in the
next step without further purification. 1H NMR (400 MHz, chloroform-d) δ 3.49 (s, 2H), 2.97 (t,
J = 27.4 Hz, 7H), 2.59 (s, 3H), 2.05 (s, 3H), 1.83 (d, J = 18.7 Hz, 6H), 1.34 (s, 6H). ESI-MS: for
C18H29N2O3+: expected m/z = 321.2173 [M]+; found m/z = 321.2185 [M]+; 3.73 ppm error.
Compound 26:
A phosgene solution (15% in toluene, 5 mL) was cooled to 0 °C (under N2). To this was added
dropwise a mixture of 25 (1.31 g, 4.08 mmol), triethylamine (0.650 mL, 4.63 mmol) in dry
toluene (5 mL). The reaction was stirred at 0 °C for 30 min then at room temperature overnight.
The suspension was filtered off and the solvent removed under reduced pressure to yield
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activated

25,

that

was

used

in

the

next

step

without

further

purification.

4-

hydroxyisophtalaldehyde (118 mg, 0.79 mmol) was dissolved in anhydrous pyridine (3 mL), and
activated 20 (257.1mg, 0.7 mmol) was added. The reaction was stirred at room temperature
overnight and monitored by TLC. Upon completion, the solution was diluted with ethyl acetate
and washed with 1 N HCl. The combined organic layer was dried over MgSO4 and filtered.
Solvent was removed under reduced pressure, and the residue was chromatographed (silica gel,
30-70% EtOAc in Hexane) to provide compound 26 as a yellow solid with 61% yield. 1H NMR
(400 MHz, chloroform-d) δ 10.18 (s, 1H), 10.03 (s, 1H), 8.35 (d, J = 2.6 Hz, 1H), 8.12 (d, J = 8.5
Hz, 1H), 7.47 (qd, J = 14.2, 13.3, 8.1 Hz, 1H), 3.61 – 3.38 (m, 4H), 3.18 – 2.96 (m, 8H), 2.10 (t,
J = 3.6 Hz, 3H), 1.95 – 1.84 (m, 6H), 1.40 (d, J = 3.1 Hz, 6H). ESI-MS: for C27H32N2O7:
expected m/z = 497.2283 [M+H]+; found m/z = 497.2282 [M+H]+; 0.20 ppm error.
Q3Cy probe:
A mixture of Compound 26 (41 mg, 0.08 mmol), NaOAc (14.6 mg, 0.18 mmol), and compound
15 (50.57 mg, 0.18 mmol) was dissolved in 2 mL Ac2O. The reaction mixture was stirred for 30
minutes at 80 oC under an N2 atmosphere, and the reaction was monitored by RP-TLC (50%
ACN in water, Rf = 0.38). After completion of the reaction, the solvent was removed under
reduced pressure, and the residue was diluted with 3 mL H2O, 3 mL ACN, 300 mL of AcOH and
this was chromatographed (C-18 silica, gradient of 10%-90% AcCN in H2O) to provide Q3Cy
(49 mg, 0.04 mmol) in 60% yield. 1H NMR (500 MHz, chloroform-d) δ 9.34 (d, J = 7.0 Hz, 1H),
8.57 – 8.16 (m, 5H), 7.90 – 7.72 (m, 2H), 7.62 – 7.39 (m, 7H), 5.23 – 4.97 (m, 4H), 3.65 – 3.42
(m, 4H), 3.20 (s, 1H), 3.11 – 2.99 (m, 7H), 2.90 – 2.78 (m, 4H), 2.41 (d, J = 11.1 Hz, 4H), 2.13 –
2.07 (m, 3H), 1.89 (d, J = 3.0 Hz, 6H), 1.83 (d, J = 5.5 Hz, 6H), 1.78 – 1.69 (m, 6H), 1.40 (d, J =
3.9 Hz, 6H).

13

C NMR (101 MHz, chloroform-d) δ 191.08, 187.67, 182.95, 181.79, 172.73,

154.62, 154.50, 152.87, 146.61, 144.18, 143.34, 143.06, 140.47, 140.38, 138.17, 138.08, 136.59,
132.74, 130.50, 130.15, 129.70, 127.36, 124.25, 122.89, 122.62, 154.44, 114.91, 114.30, 52.89,
52.30, 47.54, 47.21, 46.79, 46.46, 46.21, 45.00, 37.56, 36.63, 36.21, 36.03, 35.77, 35.25, 33.71,
28.66, 27.03, 26.85, 25.33, 20.83, 14.35, 12.73, 12.12. ESI-MS: for C55H66N4O11S2: expected m/z
= 1023.4243 [M+H]+; found m/z = 1023.4232 [M+H]+; ppm error, and expected m/z = 512.2158
[M+2H]+2; found m/z = 512.2162 [M+2H]+2; 0.78 ppm error.
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4.2.5

Enzyme kinetics
hNQO1. All fluorescence measurements (λex = 590 nm, λem = 690 nm) were obtained at

room temperature with solutions composed of pH 7.4, 0.1 M PBS/0.1 M KCl/0.007% BSA.
Solutions of β-nicotinamide adenine dinucleotide, reduced disodium salt (NADH, SigmaAldrich) were made with the PBS buffer so that subsequently prepared solutions possessed a
final concentration of 1 × 10−4 M β-NADH in each assay. Solutions consisting of 2 × 10−6 to
5 × 10−5 M Q3Cy were made using the NADH stock. A 5 µg mL-1 stock solution of recombinant
hNQO1 (Sigma-Aldrich) was prepared using the same buffer as above so as to give 2.5 × 10−6 g
hNQO1 per assay. Each assay was performed in a quartz fluorescence cuvette containing 0.75
mL Q3Cy solution and was initiated by the addition of 0.75 mL hNQO1 solution. Measurements
were collected every 30 s for 10 min. Fluorescence units were converted to concentration by
relating the signal increase to a fluorescence signal derived from a known concentration of Cy
reporter. Plots of velocity versus Q3Cy concentration were used to obtain apparent Km and Vmax
values from nonlinear least-squares analysis employing algorithms developed by Cleland for
Michaelis−Menten kinetics.21
4.2.6

Quantum yield
Fluorescence quantum yield measurements were carried out using dilute dye solutions

where absorbance was kept between 0.02–0.08. An amount of 1.5 mL from these solutions was
transferred to 1-cm × 1-cm quartz cuvettes and subjected to fluorescence measurements.

ΦF(X) = (As/Ax) (Fx/Fs) (nx/ns)2 ΦF(S)

Equation 1

The quantum yield of Cy were calculated relative to CY 5.5 (Φ = 0.23)22 using Equation
1, where Φ F is the fluorescence quantum yield, A is the absorbance at the excitation wavelength,
F is the area under the corrected emission curve, and n is the refractive index of the solvents
used. Subscripts S and X refer to the standard and the unknown, respectively. In this equation,
absorbance A accounts for the number of absorbed photons, and the area F accounts for the
number of emitted photons. The quantum yield of Φ(Q3Cy) was obtained in aqueous media (0.1
M phosphate buffer, pH =7.4) and was calculated to be 0.06.
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Figure 4.3
Normalized absorption (dashed), emission (solid) spectra of the donor-acceptor
dye series (a–e), in pH 7.4, 0.1 M phosphate buffer. T = 25 °C.
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According to a published procedure by Shabat et al. I synthesized a series of dyes (a–e)
comprising anionic, cationic and zwitterionic charged dyes.18-19,23 Dyes were constructed using
three different dialdehyde species (4-hydroxyisophtalaldehyde, 21, 22) by condensing them with
different picolinium and indolinium acceptor groups.19 As depicted in Figure 4.1, initial
deprotonation of the phenol results in a phenolate donor, which donates its electrons to the
conjugated acceptor groups. This generates a resonance species that has an extended πconjugated backbone, resulting in increased emission wavelengths in the NIR region. Dye e
showed the furthest NIR emission at around 715 nm, while b and d showed the lowest NIR
emission around 625 nm (Figure 4.3). However, Dye c was selected as a potential candidate for
further studies in developing a probe for NQO1, due to its large Stokes shift, increased water
solubility, brightness (εΦ), and neutral zwitterionic charge state.
4.3.2

Spectroscopic properties of Q3Cy probe and Cy reporter
Q3Cy was synthesized using a four-step synthetic route outlined in Scheme 4.2. The

trimethyl quinone propionic (Q3PA) acid was first coupled to a Boc-protected dimethylethylene
diamine (2) linker, followed by Boc deprotection to yield 25 as the ammonium TFA salt. 4hydroxyisophtalaldehyde was then coupled to 25, and subsequent condensation with two
equivalents of indolium sulfonate groups (15) gave Q3Cy in good yields. The indolium-3-propylsulfonate groups provided good water solubility and also prevented aggregation, both properties
being desirable for biological applications of Q3Cy.
The spectroscopic properties (Figure 4.4) of Q3Cy and Cy showed striking difference in
buffered aqueous media, with Q3Cy having its maximum absorption centered at 391 nm with an
extinction coefficient, ε, of 1.09 × 104 M−1cm−1, while Cy has two absorption bands, with one
centered at 477 nm (ε = 2.98 × 104 M−1cm−1) and the other at 590 nm (ε = 3.30 × 104 M−1cm−1).
Importantly, the absorbance spectra of the Q3Cy probe and the Cy reporter showed two unique
features important for the development of activatable probes. Firstly, as depicted in Figure 4.4,
Cy

Cy

Q3Cy shows minimal absorption both in the red ( λabs = 590 nm) and the orange ( λabs = 477 nm)
region where Cy has its maximum absorbance values; this is a desirable spectroscopic feature for
development of “turn-on” probes. Secondly, the good overlap in absorbance of Q3Cy and Cy in
the green region could be beneficial for the development of a ratiometric probe.
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Figure 4.4
The absorbance properties of the Q3Cy probe and the Cy reporter color coded
according to the different regions: red and orange, minimum absorption of Q3Cy and maximum
absorption of Cy; green, overlap region. Absorbance recorded in pH = 7.4, 0.1 M PBS;
T = 25 °C.
Therefore, in order to assess the emission properties in the red, orange, and green regions,
solutions of both Q3Cy and Cy were excited at different wavelengths (Figure 4.5).
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Figure 4.5
The fluorescence emission of, a) Q3Cy, and b) Cy at different excitation
wavelengths. Red, λex = 590 nm; orange, λex = 470 nm; and green, λex = 440 nm. All performed
in pH = 7.4, 0.1 M PBS; T = 25 °C.
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The Q3Cy probe has its maximum emission in the green region, but showed minimum
emission in the red and orange regions. On the other hand, Cy showed its maximum emission
signal in the red region, and showed decreasing emission intensity in orange and green regions
respectively.
4.3.3

Q3Cy as a “turn-on” probe
Aqueous solutions of Q3Cy probe were virtually non-fluorescent at the maximum

excitation wavelength of the Cy reporter, as noted by a weak emission band at 690 nm. However,
the Cy reporter has a very significant emission at 690 nm (Figure 4.6). This large ∼125-fold
difference in fluorescence is desirable for developing a turn-on response, as this is particularly

∼125 fold signal
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Figure 4.6
Left, emission spectra of 2.5 × 10−5 M solutions of Q3Cy (yellow) and Cy (blue),
Right, red excitation region where the solutions were excited (λex = 590 nm). Both experiments
were carried out in pH 7.40, 0.1 M PBS; T = 25 °C.
of using Q3Cy as a “turn-on” probe for NQO1. The sequence of events that leads to the release of
the free Cy reporter is illustrated in Scheme 4.3. The initial reduction (step i) of Q3Cy forms a
hydroquinone species, which then through collapse of a tetrahedral intermediate yields a stable
lactone (step ii). In the subsequent step, the dimethyl aminoethylenediamine linker is removed to
form a stable cyclized urea together with the free Cy reporter (step iii).
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Scheme 4.3 Schematic representation of a series of reactions after NQO1 activation of Q3Cy
probe, resulting in the release of the free Cy reporter.
Therefore, in order to demonstrate this behavior, buffered solutions (pH = 7.4) of Q3Cy
containing NADH (100 µM) were incubated with human NQO1 (2.5 µg), and the enzymatic
reaction was monitored through fluorescence spectroscopy. As expected, interaction of Q3Cy
with NQO1 as noted in emission spectra obtained by 590 nm excitation (λex), leads to
fluorescence spectra with a turn-on peak centered around 690 nm in the near-infrared region; the
graph in Figure 4.7 shows the increase in signal intensity over time.
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Figure 4.7
Human NQO1 enzyme-initiated switching on of Cy reporter. Left: wavelength
scan of 1.5-mL solution of 2.5 × 10−5 M Q3Cy and 2.5 µg of hNQO1 in pH 7.40, 0.1 M PBS.
Right: red excitation region where the solutions were excited (λex = 590 nm); T = 25 °C.
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4.3.4

Stability and enzymatic reactivity of Q3Cy
High stability and faster kinetics in aqueous media are important factors in the design of

imaging probes for use in biological milieu. Thus, aqueous solutions of Q3Cy in the presence and
in the absence of NQO1 enzyme were excited at 590 nm, and the emission was observed at 690
nm to study the release of the Cy reporter. As depicted in Figure 4.8 (red line) Q3Cy
Q3Cy + NQO1

100
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Q3Cy
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Figure 4.8
Time-course fluorescence of 1.5-mL solution of 2.5 × 10−5 M Q3Cy and 2.5 µg of
NQO1 in pH 7.40, 0.1 M PBS Q3Cy (λex = 590 nm, λem = 690 nm, black). Red line shows the
stability of Q3Cy in the absence of NQO1 under same solution conditions; T = 25 °C.
showed excellent stability in the absence of NQO1 enzyme in aqueous PBS media for the
intended time frame for the fluorescence measurements. Importantly Q3Cy exhibited fast
activation (Figure 4.8, black line) in the presence of human NQO1, revealing the maximum Cy
release in ∼40 minutes. As demonstrated in the previous chapter for Q3Nap, NQO1 activity
towards the Q3Cy probe was measured through the formation of fluorescent Cy reporter, with
different concentrations of the Q3Cy probe (2−50 × 10−6 M) in the presence of fixed amount of
NQO1 enzyme (2.5 µg/mL). The fluorescence intensity at 690 nm was measured and converted
to concentrations of free Cy reporter using a calibration curve. From these experiments, the
initial rate of product formation, V (µmol min−1mg.hNQO1−1), was calculated and plotted as a
function of Q3Cy concentration (Figure 4.9). Apparent kinetic parameters were then obtained by
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fitting the data in Figure 4.9 to the Michaelis-Menten equation, which provides the Michaelis
constant (Km) = 2.19 µM, maximum velocity (Vmax) = 0.13 µmol min−1mg.hNQO1−1, catalytic
constant (kcat) = 4.02 min−1, and catalytic efficiency (kcat/Km) = 2.11×105 M−1min−1.
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Figure 4.9
Kinetics of human NQO1 (2.5 µg/mL) with Q3Cy (2−50 ×10−6 M) in pH 7.4, 0.1
M phosphate buffered saline. Values (n = 3) are the average ±1 sample standard deviation. The
curve is the best fit to the average data. T = 25 °C.
These results provided evidence for the NQO1–initiated enzymatic reduction of the Q3Cy
probe under physiological conditions that results in efficient release of the Cy reporter, and it is
clear this activation is faster compared to the Q3Nap activation described in the previous chapter.
The use of a more flexible N,N-dimethyl amino linker (compare to the more rigid p-aminobenzyl
alcohol linker used in Q3Nap), and the use of negatively charged sulphonate groups allowed the
Q3Cy probe to have a favorable geometry and interactions at the active site of the NQO1
enzyme, thus providing faster activation kinetics compared Q3Nap. However, molecular
modeling and molecular docking studies are needed to provide a definitive answer for this
behavior.
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4.3.5

Q3Cy as a “naked-eye” colorimetric probe
An important feature I observed in fluorescence turn-on emission experiments is the

change in solution color, initially being yellow, and after completion of the reaction the solution
became blue; the latter is the characteristic color for aqueous Cy reporter. This prompted the
possibility of Q3Cy use as a colorimetric probe in NQO1 identification. To test this, the
absorbance profile of the NQO1 reduction of Q3Cy substrate was carried out, using similar
solution conditions to those in the fluorescence measurements. As expected, the enzymatic
reaction led to a change in the color of the solution from yellow (Q3Cy) to deep blue (Cy),
indicating production of the Cy reporter. Furthermore, the change in color also makes Q3Cy a
potential candidate for future ex vivo tissue imaging studies and quantification assays for NQO1
biomarker. Isosulphan blue is an absorbance–based imaging agent used in identification of tumor
sentinel nodes in lymphatic systems;24 however, such agents require high dye concentrations,
limiting their applicability in routine clinical applications. Interestingly, as the Q3Cy probe
absorbance around 390 nm decreased, two new absorption bands started to appear around 470
nm and 590 nm, with a clear isosbestic point centered around 430 nm (Figure 4.10). The
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Figure 4.10 Colorimetric response of Q3Cy probe in the presence of human NQO1. Left,
absorbance profile; and right, change in color from yellow to deep blue for a solution of 2.5 ×
10−5 M Q3Cy and 2.5 µg/mL of hNQO1 in pH 7.4, 0.1 M PBS; T = 25 °C.
observation of an isosbestic point is indicative of a ratiometric response and provided a new
route to study Q3Cy probe activation by NQO1 enzyme.
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4.3.6

Q3Cy as a “ratiometric” probe
To study the ratiometric response of the probe, a solution of Q3Cy (25 µM) and NQO1

(2.5 µg/mL) in PBS (pH = 7.4) with NADH (100 µM) was excited at 440 nm. Similar to the
absorbance measurements, an emission band corresponding to the probe at 515 nm decreased in
intensity, and concomitantly two new emission bands started to appear around 550 nm and 690
nm that correspond to production of Cy reporter (Figure 4.11). It is important to note that, due to
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Figure 4.11 NQO1 enzyme-initiated ratiometric response with the Q3Cy probe, Left:
wavelength-scan of 1.5-mL solution of 2.5 × 10−5 M Q3Cy and 2.5 µg of hNQO1 in pH 7.40,
0.1 M PBS; Right: green excitation region where the solutions were excited (λex = 440 nm);
T = 25 °C.
Cy
Cy
the excitation energy being closer to the λ470
band than the more red-shifted λ590 band, the

former showed higher emission intensity around 550 nm in comparison to the near-infrared band
centered around 690 nm. However both emission bands showed increase in intensity with time
indicating release of the Cy reporter.
To examine the possibility of quantitative analysis of NQO1 activity, I conducted
experiments of concentration-dependent monitoring of enzymatic reaction with aqueous
solutions of Q3Cy. In the assay shown in Figure 4.12, the Q3Cy probe concentration (25 µM) was
kept constant, while the NQO1 concentration was varied from 0.5 to 20 µg/mL, and the
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Figure 4.12 Graphs a–g represent the ratiometric response of 25 µM Q3Cy with 100 µM
NADH in the presence of different concentrations of NQO1 enzyme (0.5, 1, 2.5, 5, 10, 15, 20
µg/mL) in pH 7.4, 0.1 M PBS. The arrows indicate the signal response, decreasing (515 nm,
purple) and increasing (550 nm, blue and 690 nm, green) over time; λex = 440 nm, T = 25 °C.
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fluorescence intensity was measured with time. As shown in Figure 4.12 the fluorescence
intensity at 515 nm decreases, and the two Cy bands at 550 nm and 690 nm increase with
increasing NQO1 concentration. To further evaluate this ratiometric response, the dependency of
the corresponding peak intensity ratios (I550/I515) was plotted against the NQO1 concentrations,
which showed an exponential increase over the enzyme concentration range studied (Figure
4.13).

Figure 4.13 Dependence of the emission intensity ratios (I550/I515) of Q3Cy (25 µM) on the
concentration of NQO1 enzyme (0.5–20 µg/mL), in pH = 7.4, 0.1 M PBS, λex = 440 nm;
T = 25 °C.
However, the ratiometric fluorescent plot (I550/I515) versus time showed a linear
relationship with high correlation coefficients (Figure 4.14). This type of a ratiometric
fluorescent response is particularly important In the development of NQO1 enzyme
quantification assays. This is because Q3Cy employs simultaneous readings of three fluorescent
signal intensities in the presence of NQO1, which helps account for the reacted and unreacted,
probe concentrations minimize interfering factors providing an amplified signal output.
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Figure 4.14 Time–dependent ratiometric fluorescence response (I550/I515) of Q3Cy (25 µM) for
different concentrations of NQO1 enzyme (0.5–20 µg/mL), in pH = 7.4, 0.1 M PBS. λex = 440
nm; T = 25 °C.
4.3.7

Q3Cy for in vitro and in vivo imaging of cancer cells that overexpress NQO1
The lack of switching on of the dormant fluorescence in the absence of the enzyme, the

large difference (∼100 nm) between the absorption and the emission of the Cy reporter, and the
near-infrared emission range of reporter bodes well for providing high signal-to-background
ratios for in vivo imaging experiments with Q3Cy probe. It is also noteworthy to mention that the
unique feature of the Q3Cy probe having “turn-on” and “ratiometric” responses is unprecedented
in the context of the previous work in the McCarley group. Recently, Kobayashi et al. reported a
bacteriochlorin-based dye that has two different excitation wavelengths so as to image peritoneal
ovarian cancer implants both at the surface (green light excitation), and at shallow depths (red
light excitation) in the abdominal cavity with high sensitivity and specificity.25 This type of a
two-mode response is beneficial in diagnosing both surface level and more deeply seated
diseased tissues. Another important feature of the Q3Cy probe is its high water solubility, which
is beneficial for in vivo imaging experiments. The colorimetric nature of Q3Cy could be useful
for ex vivo tissue staining experiments for studying the presence or the absence of NQO1.
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The fast activation, hydrolytic stability, and multi-mode (ratiometric, turn-on,
colorimetric) response of the Q3Cy probe is quite promising for use in cancer cell imaging. The
Q3Cy was designed as a neutral zwitterionic probe to promote good cell penetration. However,
preliminary studies performed by one of my colleague Bijeta Prasai, using NQO1-positive
colorectal cancer cell line (HT29) showed unexpectedly low probe uptake, thus offering low
signal emission for the released Cy reporter (Figure 4.15).

Figure 4.15 Microscopy images of live hNQO1-positive HT29 colon cancer cells: control
experiment without the presence of Q3Cy (a, b, c), and after incubation at 37 °C with 5 × 10−5 M
Q3Cy (d, e, f). Confocal images in a and d; differential interference contrast in b and e; and
overlay image c and f. For images of cells exposed to Q3Cy samples were excited using a 633 nm
line of a HeNe laser, and the spectral emissions were collected between 655 and 735 nm. Scale
bar = 20 μm.
Although there is precedence for cellular penetration of sulfonate containing zwitterionic
dyes (e.g., Cy 5 and ATTO655 used in cellular protein imaging),26-27 the negatively charged
sulfonate groups could hinder the membrane permeability of Q3Cy. Also, it is of common
practice to protect negatively charged phenoxyl and carboxyl groups (e.g. coumarins, resorufin,
fluorescein) as cleavable phenolates and carboxyesters to enhance cellular delivery, such
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methods are not useful for protection of sulfonate groups.28-31 The Ting lab at Massachusetts
Institute of Technology demonstrated a facile route for ester protection of sulfonated
fluorophores for intracellular protein imaging.32 Inspired by their idea, The McCarley group is
currently in the process of synthesizing a protected Q3Cy probe for better cellular delivery. Also
I believe that once the probe gets inside cells, the esterases commonly found in the cell will
cleave the sulfonate-protecting groups, yielding Q3Cy for the activation by the NQO1 enzyme
(Scheme 4.4).
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Scheme 4.4 A new route for cellular delivery of Q3Cy, by protection of sulfonate groups as
esterase-cleavable acetoxy esters, and probe activation in cellular media.
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CHAPTER 5
SUMMARY, CONCLUSIONS, AND OUTLOOK: A NEW GENERATION OF
HEPTAMETHINE CYANINE-BASED PROFLUOROPHORES
5.1

Summary and Conclusions
The overall goal of this research was the design, synthesis and evaluation of

fluorescence-based activatable probes for detection and identification of human cancer enzyme
NQO1 with high signal-to-background ratios. The outcomes of the work presented in this
dissertation are innovative upon examination of previous work done in McCarley research lab
and other groups on enzyme activatable probes, as the outcomes provide important contributions
to the development of such fluorescence-based activatable probes for future in vivo imaging
experiments.
In the second chapter I have shown the synthesis of two different tripartite probes (orthoand para-) composed of a trimethyl-locked quinone propionic acid (QPA) trigger group, an Nmethylaminobenzyl alcohol linker, and 4-nitroaniline reporter, and I demonstrated their selfimmolative behavior. The dithionite-initiated reduction of the quinone trigger group and
subsequent linker decomposition resulted in the release of 4-nitroaniline reporter. The reactant
probes disappearance (327 nm) and the product nitroaniline formation (391 nm) were monitored
by UV/visible spectroscopy, and it was concluded that 1,6-para elimination was comparatively
faster than 1,4-ortho elimination under the conditions here. Thus, the 1,6-para elimination route
was selected in the design of a NQO1-activatable probe.
In the third chapter, I have presented the synthesis and properties of a novel turn-on
probe, Q3Nap (Figure 5.1), and its biological evaluation in detecting the cancer-associated
enzyme NQO1. Q3Nap consists of a QPA trigger group linked to a fluorescently masked
naphthalimide by N-methyl-p-aminobenzyl alcohol, NMPABA, so as to establish an electronwithdrawing carbamate connection. This changed the electron density around the naphthalimide
scaffold so as to modulate the fluorescence properties of the Q3Nap probe through a push-pull
internal charge transfer (ICT) mechanism. This fluorescence modulation is reflected in the
spectroscopic measurements, as the free Nap reporter showed a red shift of roughly 50 nm in
both absorbance and emission spectra vs those of the Q3Nap probe. Interestingly, due to a unique
photo-induced electron transfer quenching mechanism, Q3Nap showed a very weak emission
band having a low quantum yield of 0.002. The PeT based quenching is supported by outcomes
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based on voltammetric measurements performed on Q3Nap, where a favorable free energy
change for both the oxidative electron transfer (OeT, −0.98 eV) and the reductive electron
transfer (ReT, −1.44 eV) was obtained. The free naphthalimide reporter exhibited a high
quantum yield of 0.19, thereby showing an intense emission intensity change for dithioniteinitiated switching on of the cloaked Q3Nap probe. This turn-on response was rapid, and a
maximum Nap release was observed in roughly ∼15 min under physiologically relevant
conditions, pointing to the rapid self-immolative cleavage of the N-methyl-p-aminobenzyl
alcohol linker. Also this conversion was confirmed by mass spectrometry analysis of Q3Nap
solutions treated with dithionite, where I observed all three products, namely, lactone, benzyl
alcohol linker, and naphthalimide fluorophore; this provides further evidence for the proposed
mechanism of Q3Nap activation. In addition the rate of Nap release is comparable with what I
observed for the nitroaniline-based trigger probe described in the second chapter.

Figure 5.1
Synthesized and proposed NQO1 activatable small-molecule profluorogenic
probes. The color of the structure indicates the maximum emission wavelength of the
fluorophore.
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Under in vitro conditions, buffered solutions (pH = 7.4, 0.1 M PBS) of Q3Nap (2−60 µM)
incubated with hNQO1 (40 µg) and its cofactor NADH (100 µM) exhibited a steady increase in
fluorescence, pointing to a relatively fast rate of Nap production; control experiments with
NADH alone did not yield significant changes in fluorescence suggesting high stability of Q3Nap
in aqueous media. Furthermore, I was able to demonstrate high selectivity of Q3Naps toward
NQO1 over its isoenzyme NQO2 by performing in vitro enzyme kinetic experiments that
revealed ineffective reporter release over time. Bijeta Prasai one my colleagues in the McCarley
group, performed cell assays to investigate the possibility of Q3Naps use in differentiating types
of cancer cells based on NQO1 content (positive vs negative). Confocal fluorescence images
exhibited high Q3Nap probe uptake and its activation in hNQO1-positive HT29 cancer cells,
while minimum signal was observed in hNQO1-negative H596 cells, leading to a highly
selective differentiation between the two cancer cell lines. Importantly, statistical analysis of
confocal cell images for positive and negative cancer cells resulted in a very high positive-tonegative ratio (PNR, ∼500), an unprecedented number in the context of previous work in the
litreature. However, Q3Nap displayed slower enzymatic activation is noted by its high Km = 10.4

µM and low Vmax = 0.00225 µmol min−1mghNQO1−1 in comparison to a previously synthesized
naphthalimide based probe, Q3NI.1 Even though the self-immolative N-methyl-p-aminobenzyl
alcohol linker provided faster elimination kinetics via quinone methide formation, it appears to
conformationally lock the molecule, which prevent favorable binding at the active site of the
NQO1 enzyme.
In order to achieve fast enzymatic activation, I have synthesized a second probe Q3Cy,
comprised of the quinone trigger group, an N,N-dimethylethylenediamine linker, and a cyaninebased, near-infrared fluorophore (Figure 5.1). The cyanine fluorophore used had a large Stokes
shift of ∼100 nm and has an excitation maximum of 590 nm with a corresponding emission
maximum at 690 nm. Similar to the Nap fluorophore described earlier, the cyanine fluorophore
has modulated fluorescence based on internal charge transfer mechanism. However, unlike
Q3Nap, attachment of the QPA ethylenediamine linker to the cyanine fluorophore did not quench
the fluorescence of the Q3Cy probe; instead Q3Cy exhibited an absorption and a relatively
intense emission around 390 nm and 515 nm, respectively. Importantly, the sulfonated groups of
the cyanine scaffold provided better water solubility, allowing all the kinetic experiments to be
performed in aqueous media without using any organic cosolvents. Even though the probe was
134

not quenched, it did not show any emission upon excitation at the maximum absorption
wavelengths (470 nm and 590 nm) of the free Cy reporter, allowing Q3Cy to behave as a turn-on
probe in the presence of NQO1 enzyme. This type of probe quenching and enzyme-initiated
fluorescence turn-on in the near-infrared region is beneficial for providing higher signal-tobackground ratios for in vivo imaging applications. Also, the flexible ethylene diamine linker
resulted in faster enzyme kinetics (Vmax = 0.1303 µmol min−1mg.hNQO1−1) and better binding
affinity (Km = 2.19 µM) at the NQO1 active site in comparison to Q3Nap.
Interestingly, the enzymatic activation of Q3Cy resulted in a rapid color change from
yellow to blue, and a ratiometric absorbance profile was observed that had a clear isosbestic
point around 440 nm. Another unique and important feature of the Q3Cy probe was its
ratiometric emission profile, which upon excitation at 440 nm showed an isoemission point
around 540 nm. This type of ratiometric activity is particularly useful in enzyme quantification
assays for providing highly sensitive and quantitative responses depending on enzyme
concentration. Q3Cy was designed as a zwitterionic species to bear an overall neutral charge in
the molecule so as to provide better cellular permeability for identification of intracellular NQO1
enzyme content. However, preliminary studies with HT29 cell lines did not show appreciable
Q3Cy uptake, possibly due to presence of sulfonate groups in the probe molecule. Currently,
protection of the sulfonate groups by acetoxy-esters is underway. I believe that this derivatization
will offer enough hydrophobicity by masking the negative charges of the sulfonate groups so as
to provide efficient cellular uptake. Once onside the cell the esterase-labile sulfonate protecting
groups will be cleaved off, to yield a trappable negatively charged Cy reporter that can be
activated by NQO1 inside the cell.
5.2

Outlook

5.2.1

New generation of NIR activatable probes based on heptamathine cyanine scaffold
In a parallel project, I was interested in developing imaging probes with a heptamethine

cyanine scaffold that have long excitation/emission wavelengths in the NIR region.
Heptamethines are good candidates for fluorescent reporter labeling techniques, because the
meso-position in their conjugated polymethine chain can be easily occupied by various
nucleophiles (Figure 5.2).2
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The heptamethine conjugates are widely used in protein labeling agents as “always-on”
probes and show minimal change in their spectral properties. In addition, a much smaller singlet
excitation energy, ΔE00 in the Rehm-Weller equation has hampered their potential use as tunable
fluorescent probes via fluorescence modulation by photo-induced electron transfer (PeT)
mechanisms.2
a

b
NH

Cl
N

N

N

N

Figure 5.2
New generation of heptamethine-based dyes by amine substitution: a) chlorosubstituted, and b) methylamine-substituted heptamethine fluorophores.
However, Peng et al. demonstrated displacement of Cl in the polymethine linker by
amine substitution could significantly alter the spectral properties of the heptamethine scaffold.2-3
Based on this, I propose an NQO1-activatable probe whose fluorescence can be turned on,
Figure 5.3.
O
O
Enzymatic
reduction
N

Cyclizative
removal of
Trigger group

O

N

O

N

NH
N

N

O

Q3TCy probe

TCy reporter
OH

Figure 5.3
Mechanism of enzymatic activation of a first-generation, heptamethine-based
Q3TCy probe.
This idea will be utilized in the design of a new generation of fluorescent probes for
NQO1 detection. Q3TCy has been designed such that the quinone propionic acid trigger group is
directly coupled to the TCy reporter, thereby affording three different outcomes: 1) the
carbamate linkage between the TCy and quinone propionic trigger group attenuates the electron
density on the amine, thus shifting the absorption maximum to a longer wavelength; 2) it is
anticipated that quenching can be achieved through photo-induced electron transfer (PeT) from
136

the indocyanine moiety to the quinone trigger group; and 3) fast enzyme kinetics will occur upon
removal of the eliminating/cyclizative attachments (Figure 5.3). According to the proposed
enzymatic activation depicted in Figure 5.3, the reduction of the quinone trigger group followed
by the lactone formation directly yields the free TCy reporter, bypassing the linker selfimmolation/cyclization step that was required for the previous two probes, Q3Nap and Q3Cy
respectively. The synthesis of the Q3TCy probe is still under investigation, and I was able to
synthesize the free TCy reporter; and its spectroscopic properties are depicted in Figure 5.4.
Aqueous solutions (1% DMSO as cosolvent) of TCy displayed a broad absorption band centered
around 610 nm and a emission band centered around 725 nm.

Figure 5.4
Normalized absorbance and emission of TCy reporter in 1% DMSO, pH = 7.4,
0.1 M phosphate buffer. T = 25 °C.
The large Stokes shift (>120 nm) and the near-infrared emission of TCy are two
important features desirable for design of imaging probes for in vivo imaging applications. In
preliminary cellular imaging experiments (performed by Bijeta Prasai), efficient uptake of the
free TCy reporter in NQO1-positive HT-29 cells was observed (Figure 5.5). This proves that the
overall positive charge delocalized through the cyanine backbone does not affect the
permeability of TCy through the cell membrane. Therefore, I believe that because Q3TCy is
expected to have the same delocalized positive charge, it could also enter the cell as efficiently as
the free TCy reporter. It is important to note that the initial coupling reaction of Q3PA and TCy
performed with EDCI/pyridine resulted trace amounts (characterized through ESI-MS) of the
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Q3TCy probe, and currently, the synthesis of Q3TCy with different coupling conditions is in
progress.

Figure 5.5
Preliminary microscopy images of hNQO1-positive HT29 colon cancer cells after
incubation at 37 °C with 2.5 × 10−5 M TCy reporter: a) confocal image, b) differential interface
contrast, c) overlay. Scale bar = 20 μm.
Water solubility is an important requirement for in vivo imaging applications of the
Q3TCy probe, thereby minimizing aggregation for desirable high emission intensities.
Incorporation of either sulfonate or carboxylic acid groups in the heptamethine scaffold could
provide better water solubility; however, this could also lead to decreased cell permeability due
to the overall negative charge associated with such functionalizations. Possible future Q3TCy
probe derivatizations are shown in Figure 5.6.
O

a

b

O
O

O

O

O

O
N

N
N

O
O

O

O

S

N

O

OEt

EtO
O

N

O

O

O

O
S

O

O
N

O
O
O

Figure 5.6
Possible future target probes for NQO1 imaging based on the heptamethine
scaffold. a) carboxyl and b) sufonate protection with esterase-cleavable acetoxy and sulfonate
ester functional groups.
These carboxy- and sulfonate-protected probes do not yield altered overall net charge,
thus leading to better cellular uptake than their unprotected counterparts. Once inside the cell, the
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probe is expected to be hydrolyzed by intracellular esterases, and then upon interaction with the
NQO1, enzyme the free negatively charged reporter is released for accumulation inside the cell.
Taken together, the work presented in my dissertation provides design concepts for the
development of a new generation of enzyme-activatable, fluorescence-based substrate probes for
imaging applications with high signal-to-background ratios. With a better understanding of the
enzymatic activity and improvement of the fluorescent properties these types of imaging probes
in hand, has great potential to translate their use into clinical applications in the future.
5.3

Experimental

5.3.1

Synthetic material and methods (Scheme 5.1).
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Scheme 5.1
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Synthesis of Q3TCy probe and TCy reporter.

Compound 27
A solution of 40 mL of N,N-dimethylformamide in 40 mL dichloromethane was cooled to −6 oC,
and phosphorus oxychloride (37 mL) was added dropwise with stirring, followed by
cyclohexanone (10.0 g, 0.10 mol). The mixture was refluxed for 3 h. After cooling, the solution
was poured onto 200 g of ice and allowed to stand overnight. 27 was collected as a yellow solid
(8.04 g, 46.5 %). ESI-MS: for C8H9ClO2: expected m/z = 173.0364 [M+H]+; found m/z =
173.0365 [M+H]+; 0.58 ppm error.
139

Compound 28
Under the nitrogen atmosphere, to a three-neck flask containing compound 27 (11.23 g, 36
mmol) in 70 ml acetic anhydride, sodium acetate (2.95 g, 36 mmol) was added. The solution was
heated to 70 oC for 1 h. After of which, the reaction solution was poured to potassium iodide
aqueous solution, stirred. The generated mixture was filtered, and the precipitate was washed
thoroughly with diethyl ether. 28 was obtained as green solid was obtained (7.88 g, 68.6 %). 1H
NMR (400 MHz, chloroform-d) δ 8.37 (d, J = 14.1 Hz, 2H), 7.48 – 7.35 (m, 4H), 7.30 – 7.18 (m,
4H), 6.23 (d, J = 14.1 Hz, 2H), 4.27 (q, J = 7.2 Hz, 4H), 2.77 (t, J = 6.1 Hz, 4H), 2.00 (m, 2H),
1.74 (s, 12H), 1.48 (t, J = 7.2 Hz, 6H).

13

C NMR (101 MHz, chloroform-d) δ 171.98, 150.71,

144.58, 141.86, 141.26, 128.97, 127.59, 125.44, 122.41, 110.83, 101.14, 49.46, 40.22, 28.18,
26.92, 20.81, 12.60. ESI-MS: for C34H40ClN2+: expected m/z = 511.2875 [M]+; found m/z =
511.2871 [M]+; 0.78 ppm error.
TCy
Methylamine (2M in methanol; 34 mL, 0.4 mmol) was added to compound 28 (58.3 mg, 0.1
mmol) dissolved in anhydrous DMF (10 mL). The reaction mixture was stirred at 85 oC for 3 h
under N2. The solvent was removed under reduced pressure and the crude product was purified
by column chromatography on silica gel (DCM:MeOH 100:0 to 100:1) to afford TCy as a glossy
blue solid (54.8 mg, 95 %). 1H NMR (400 MHz, methanol-d4) δ 7.70 (d, J = 12.9 Hz, 2H), 7.41–
7.24 (m, 4H), 7.13 – 6.93 (m, 4H), 5.77 (d, J = 12.9 Hz, 2H), 3.97 (q, J = 7.2 Hz, 4H), 3.46 (s,
3H), 2.66 – 2.45 (m, 4H), 1.93 – 1.79 (m, 2H), 1.65 (s, 12H), 1.32 (q, J = 6.4, 5.2 Hz, 6H). 13C
NMR (101 MHz, methanol-d4) δ 172.89, 171.61, 167.66, 144.00, 141.27, 138.32, 129.31,
123.56, 123.01, 109.50, 94.51, 61.49, 35.75, 29.06, 26.92, 22.51, 20.90, 14.48, 11.66. ESI-MS:
for C35H44N3+: expected m/z = 506.3530 [M]+; found m/z = 506.3531 [M]+; 0.20 ppm error.
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